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The corneal dystrophies are a group of inherited disorders that affect the shape or 
transparency of the cornea. The unique qualities of the cornea coupled with their mendelian 
traits make the them an ideal target for gene therapy. The main aim of this thesis is to 
investigate the potential to use CRISPR/Cas9 to treat the autosomal dominant TGFBI corneal 
dystrophies.  
Methods 
Paper II: Plasmid expressing CRISPR/Cas9 targeted to Luc2 was delivered to the cornea via 
an intrastromal pressure injection. Knockdown of luciferase was measured using an IVIS in 
vivo imager. The allele-specificity of CRISPR/Cas9 was assessed in vitro using a dual-
luciferase assay and an in vitro digestion.                                                                             
Paper III: A morpholino targeted to tgfbi was electroporated into the regenerating adult 
zebrafish tail fin, and the effect of Tgfbi knockdown was measured by the quantification of 
regenerated tissue. 10X phased sequencing and EBV-transformation of isolated lymphocytes 
was performed on a patient harbouring a R124H granular corneal dystrophy type II (GCD2) 
mutation. The phasing information was used to design allele-specific sgRNAs which were 
then tested using an in vitro digest and targeted resequencing across the target locus in 
TGFBI. qPCR was used to infer the efficiency of a dual-cut using a combination of sgRNAs. 
Paper IV: The transduction efficiency of 3 AAV-GFP serotypes in immortalised human 
corneal cells was assessed using flow cytometry. In vivo transduction of AAV-GFP following 
intracameral injection was assessed using the IVIS in vivo imager and fluorescent 
microscopy. AAV-Cas9 and AAV-sgRNA-GFP were co-injected, DNA was extracted from 
the whole cornea and TIDE analysis was performed to determine efficiency of indels. 
Results 
Paper II: The failure of a mutation-dependent approach to target 20% of TGFBI missense 
mutations was demonstrated. Comparison of two widely used allele-specific strategies 
revealed a PAM-specific approach conferred superior specificity than that of a guide-specific 
approach. The inability of S.pyogenes Cas9 to distinguish between single base pair changes in 
the guide sequence was confirmed.                                                                                      
Paper III: Knockdown of Tgfbi in the regenerating zebrafish tail fin was shown to impair 
wound healing. The ability to selectively target the mutant allele by means of non-disease-
causing SNPs, which are associated with a PAM on the same allele as the disease-causing 
mutation, was demonstrated. The addition of a 50:50 ssODN with the ribonucleoprotein 
complex was shown to significantly increases the frequency of a dual-cut event.                                                                          
Paper IV: AAV-2/9 was shown to transduce all corneal layers in vivo following a single 
intracameral injection. A dual-AAV-2/9 CRISPR/Cas9 system was shown to generate 25.7% 
within the whole cornea. 
Conclusion 
Cas9 lacks the specificity to discriminate between single base pair mismatches within the 
20bp guide sequence, however mutations within the 2bp PAM are much less tolerated. As 
such, using currently available nucleases a PAM-specific approach is necessary to 
discriminate between alleles. AAV was demonstrated as a robust vehicle to deliver gene-
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1 General Introduction 
The prospect of genome engineering as a therapeutic for genetic disease has finally come to 
light. This new era is possible due to over a century of research in which genes where 
discovered as units of hereditary, the helical structure of DNA was revealed, the central dogma 
of life was unraveled and the age of recombinant DNA was born. As the link between genetic 
variation and disease became apparent, so too did the possibility of curing disease by correcting 
or eliminating the genetic cause. The emergence of gene editing tools has enabled the 
progression of personalised medicine to the clinic and the cornea offers the ideal tissue to 
pioneer these novel treatments. 
1.1 Cornea 
The cornea is an avascular, transparent tissue found in the anterior segment of the eye. The 
main functions of the cornea are to act as a structural barrier to the outside world and to provide 
the majority of the eye’s refractive power1. The first barrier that exists between the outside 
world and the internal structures of the eye is the tear-film, which coats the cornea. The cornea 
itself can be subdivided into 3 distinct regions; an outer anterior region which comprises of 
multiple layers of proliferating epithelial cells built upon a basement membrane, a middle 
region which is a connective tissue stroma which contributes to 90% of the cornea’s thickness, 
composed of collagen lamellae interspersed with keratocytes and lastly a posterior region 
which contains a monolayer of endothelial cells attached to Descement’s membrane (Figure 
1a)2. Surrounding the cornea is the limbus which is where the limbal epithelial stem cells 
(LESCs) reside, within the limbal region the basement membrane disappears and Pallisades of 







Figure 1: a) Illustration to show the 5 different layers of the cornea; the epithelium, 
Bowman’s layer, stroma, Descemet’s membrane and endothelium. Each plays in intergral 
part in maintaining the structure and transparency of the cornea. b) Schematic of the 
Palisades of Vogt in which the LESCs are resident. They are capable of self-renewal to 
produce new LESCs and also divide asymmetrically to produce TACs that migrate 










The corneal epithelium is a non-keratinising stratified squamous epithelium and it functions as 
a physical barrier preventing foreign bodies from entering the eye. It an approximately 7 cell 
layer thick structure consisting of 3 layers of superficial flat polygonal cells which form 
intracellular tight junctions and are covered in microvilli that allow close interaction with the 
tear film, 3 layers of suprabasal wing cells whose cell membranes are linked with numerous 
desmosomes and a basal columnar cell layer which links to the basement membrane via hemi 
desmosomes2. The corneal epithelium is continually turned over every 1-2 weeks as deeper 
epithelial cells replace the superficial epithelial cells3. The LESCs are important in this process, 
LESCs are found the Palisades of Vogt in the basal region of the limbus at the corneoscleral 
junction. LESCs are capable of dividing symmetrically to self-renew and asymmetrically to 
produce daughter transit amplifying cells (TAC) that migrate centripetally to populate the basal 
layer of the corneal epithelium (Figure 1b)4,5.  
The basement membrane, known as Bowman’s layer, is made up of randomly orientated 
collagen fibrils, it provides structure and strength to the cornea and allows epithelial attachment 
to the stroma6.  The stroma consists of regularly arranged bundles of collagen with keratocytes 
located between them.2  The collagen fibrils are made up of collagen type I and type V and are 
formed into very uniform lamellae; the uniformity of this arrangement is crucial to corneal 
function, the organisation allows light transmission and maintains cornea curvature and 
strength7. The collagen lamellae are uniformly spaced from each other due to interactions with 
proteoglycans8. Keratocytes are sparsely populated between these collagen lamellae, they 
produce crystallins which contribute to corneal transparency9. Any disturbance of this highly 
ordered layer can potentially lead to corneal opacity.  
Descemet’s membrane acts as a specialised basement membrane for the corneal endothelium, 




endothelium function10. The corneal endothelium is a monolayer of cells that play an integral 
role in the hydration of the cornea11. They are considered to have a “leaky” barrier, allowing 
passage of nutrients from the aqueous humour into the corneal stroma; contrary to this the 
endothelium then simultaneously uses Na+/K+ ATPase pumps to remove excess fluid in the 
stroma to maintain corneal transparency.  Corneal endothelial cells decrease with age, injury, 
trauma or disease, such as Fuchs’ endothelial corneal dystrophy (FECD)12. They have a very 
low proliferative capacity and as the number of cells progressively decrease the remaining cells 
will spread and enlarge to compensate. As more cells are lost the remote barrier function in 
addition to the pump function of the cornea endothelium is affected, resulting in the excess 
fluid from the aqueous humour not being adequately removed causing a loss in corneal 
transparency.  
1.2 Corneal dystrophies 
Corneal dystrophies are a group of inherited, heterogeneous, bilateral disorders that affect the 
transparency or shape of the cornea13. To-date there are currently 23 characterised corneal 
dystrophies (Table 1), associated with different corneal layers14,15. The genetics behind corneal 
dystrophies is well documented; the inheritance pattern, gene locus and causative gene is 
known in ten of these characterised corneal dystrophies, with an additional four partially 
understood. Current treatment strategies are extremely limited, at present the only curative 
measure that can be taken is a partial or complete corneal transplant, however this is associated 
with its own risks such as donor shortage, graft rejection and recurrence of disease16.  
1.2.1 TGFBI corneal dystrophies 
As described corneal dystrophies are a group of diseases that affect the transparency or shape 
of the cornea. Missense mutations within TGFBI result in the accumulation of mutant TGFBI 






Table 1: List of known corneal dystrophies, including; associated inheritance 




reported to be expressed in the cornea in 199417, within the same year TGFBI and three separate 
corneal dystrophies were both linked to chromosome 5. In light of this TGFBI became a strong 
candidate for the causative gene behind these dystrophies. Subsequently, Munier et al reported 
the association of 3 different missense mutations with TGFBI to distinct corneal dystrophies. 
To-date there are 62 missense mutations within TGFBI which are clustered in hotspots in exons 
4,11,12 and 14 (Figure 2 and supplementary table 1 in paper II)14,15. R124C, R124H, R124L, 
R555Q and R555W are the most common missense mutations reported, across all ethnic 
groups18,19. TGFBI corneal dystrophies affect several layers in the cornea and collectively are 
known as the epithelial-stromal TGFBI corneal dystrophies14,15. They exhibit strong allelic and 
phenotypic heterogeneity; these missense mutations result in strikingly different corneal 
deposits and the TGFBI corneal dystrophies are divided into sub-types based on the clinical 
appearance of these corneal deposits. Broadly they can be classified as lattice corneal dystrophy 
(LCD) or granular corneal dystrophy (GCD). Prior to genetic analysis theses sub-groups of the 
TGFBI corneal dystrophies were all considered to be distinct clinical forms, the introduction 
of molecular techniques elucidated that all of these dystrophies were caused by mutations 
within TGFBI. Missense mutations within TGFBI have not been shown to cause adverse 
phenotypes in other tissues in the body. The fundamental function of the cornea is to maintain 
transparency, TGFBI corneal dystrophies result in a disease phenotype due to the accumulation 
of mutant proteins in the corneal stroma that impair its function to remain transparent. The 
pathomechanism of how mutant TGFBIp results in corneal deposits is incompletely 
understood. Extensive work has been performed to uncover the mechanisms behind the 
formation of these deposits. Potential mechanisms include susceptibility of the mutant protein 
to oxidative stress, which is induced by continued exposure to ultraviolet light (UV)20–23. In 
addition, the abnormal proteolytic processing of mutant protein has been hypothesised to result 





Figure 2: The TGFBI gene, including untranslated regions (UTRs) (shown by light blue 
shading) and introns (shown by black interlinking lines), covers ~35kb, and there are 17 coding 
exons (shown by dark blue shading). To-date 62 missense mutations within TGFBI have been 
associated with corneal dystrophies, each mutation is depicted by a single drop-down line and 
the colours correspond to the dystrophy the mutation is associated with, described in the colour 
coded key. These missense mutations are found in exons 4 to 16 of the gene; however, the 














1.2.1.1 Manifestations of TGFBI corneal dystrophies 
Classic lattice corneal dystrophy Type I (LCDI) presents as lines of amyloid deposits, arranged 
radially (Figure 3 A,B)14. Typically, it presents in the first or second decade and is associated 
with recurrent erosions and eventually causes vision loss. The most common mutation 
associated with LCDI is R124C28. Several variations of LCDI have been described and IC3D 
grouped these collectively as ‘Variant LCD’14. They are also due to other missense mutations 
within TGFBI however do not always present with characteristic thin branching refractile lines 
and in some cases erosions do not occur. 
Granular corneal dystrophy type I (GCDI) presents early in life and is associated with white 
granular opacities in the cornea, which typically increase in number and size over time (Figure 
3C)14. Corneal erosions often occur, which over time result in a loss in visual acuity. GCDI is 
predominantly associated with the R555W mutation within TGFBI28.  
Granular corneal dystrophy type II (GCDII) commonly referred to as Avellino corneal 
dystrophy, presents in the second decade of life. It is associated with granular deposits that 
form a snowflake pattern, recurrent corneal erosions and leads to a progressive vision loss 
(Figure 4)14. Avellino corneal dystrophy is caused by a R124H mutation within TGFBI28. LCDI 
deposits consist of amyloid deposits while GCDI has been shown to contain hyaline deposits, 
GCDII has both amyloid and hyaline deposits present, thus is somewhat a combination of 
lattice and granular dystrophies29. 
Granular corneal dystrophy type III (GCDIII), also known as Reis-Bücklers corneal dystrophy 
(RBCD), presents in early childhood (Figure 3D). Initial symptoms include formation of 
irregular opacities in a geographical pattern, this is followed by corneal erosions and scarring 






Figure 3: A and B) Lattice corneal dystrophy type I (LCD1) C) Granular corneal dystrophy 
type I (GCD1) D) Reis-Bücklers corneal dystrophy 













Figure 4: Avellino corneal dystrophy 












Thiel-Behnke corneal dystrophy (TBCD) manifests in a similar way to RBCD, however is less 
aggressive; it presents early in life, results in corneal erosions and an eventual loss of vision. 
However, it presents as distinctive honeycomb-shaped opacities14. TBCD can be distinguished 
from RBCD by the presence of curly fibres beneath the corneal epithelium, these fibres can 
only be detected by transmission electron microscopy30.  R555Q is the predominant mutation 
associated with TBCD28. 
1.2.1.2 TGFBI 
The TGFBI gene, including untranslated regions (UTRs) and introns, covers ~35kb, and there 
are 17 coding exons. TGFBI produces a 683-residue extracellular matrix (ECM) protein. The 
crystal structure of TGFBIp reveals it consists of a 23-residue signal peptide for secretion, a 
flexible linker, an N-terminal cysteine rich domain, four FAS1 domains and a 46-residue C-
terminal segment containing an integrin-recognition motif (RGD) 31. As previously reported 
by Lukassen et al, the N-terminal cysteine rich domain represents a novel domain32, as such it 
has been referred to as a cysteine-rich domain of periostin and TGFBIp (CROPT). Thus, 
TGFBIp consists of a CROPT domain, 4 FAS domains and a RGD enabling integrin binding 
(Figure 5). The majority of the missense mutations known to date are found in either the FAS1-
1 or FAS1-4 domains31. 
TGFBI was first identified in a human lung adenocarcinoma cell line (A549) which had been 
treated with TGFβ33, TGFBI is widely expressed in most tissues of the body34,35. The TGF 
signalling pathway affects many biological processes such as cell proliferation, differentiation 
morphogenesis, tissue homeostasis and regeneration36. However, elucidating the role of TGF 
signalling in these processes is very challenging as, depending on the cell type and conditions 
in question, the effects of this signalling pathway can have different outcomes. TGF is a large 









Figure 5: Schematic to show the different domains present in TGFBIp. The majority of 




Upon ligand binding a heteromeric complex of type I and type II serine/threonine kinase 
receptors forms. The type II receptor phosphorylates the type I receptor which then enables 
the phosphorylation of receptor-regulated SMAD proteins (R-SMAD). SMAD signalling has 
a central role in all downstream TGF effects and they act to regulate transcriptional output 
in addition to opening repressive chromatin. SMAD 2 and SMAD 3 are activated by TGF, 
Activin or Nodal signals, whereas SMAD 1, SMAD 5 and SMAD 8 are activated by BMP or 
GDP signals. Phosphorylation of these SMAD proteins then enables binding to a common 
mediator SMAD protein known as SMAD4. These activated SMAD4-R-SAMD complexes 
bind other DNA-binding transcription factors allowing the regulation of transcription. 
Reports have indicated that activation of Smad2/3-Smad 4 via TGFR1 results in TGFI 
expression37.   
1.2.2 Fuchs’ endothelial corneal dystrophy 
Fuchs’ Endothelial corneal dystrophy (FECD) is a common, age-related, inherited degenerative 
disease of the corneal endothelium which in advanced disease affects all layers of the cornea 
(Figure 6). It is identified by the presence of corneal guttae, which are excrescences of 
Descemet’s membrane. These corneal guttae are associated with a progressive loss of corneal 
endothelial cells, the loss in endothelial cells below a critical threshold results in the inability 
of the corneal endothelium to successfully dehydrate the stroma; causing fluid accumulation in 
the stroma and the development of painful epithelial bullae leading to corneal clouding and a 
reduction in visual acuity.38 In the US, approximately 5% of Caucasians over 40 years of age 
exhibit corneal guttae which may develop to corneal decompensation.39 There are two 
categories of FECD; early-onset which presents with symptoms in the first decade and late-
onset which presents with symptoms in the sixth decade.40 Within these two categories there 
are 8 subtypes, in all subtypes of FECD the genetic locus has been identified, however the 






Figure 6: Fuchs’ endothelial corneal dystrophy.  





The endothelium secretes type VIII collagen (COL8) which is a major constituent of 
Descemet’s membrane. COL8 has two isoforms, collagen type VIII isoform lpha 1 (COL8A1) 
and collagen type VIII isoform lpha 2 (COL8A2), together they form a heterotrimer that has 
a highly organised structure.41 Mutations in COL8A2 can result in instability of the heterotrimer 
and have been associated with early-onset FECD. To date 3 autosomal dominant missense 
mutations in COL8A2 (Q455K, L450W and Q455V), have been linked to early-onset FECD.42–
45 These mutations are rare, when considered alongside their late-onset FECD counterparts.  
Several genes have been associated with late-onset FECD, the most prevalent cause is linked 
to transcription factor 4 (TCF4). 70% of reported FECD cases are associated with TCF4. A 
genome wide association study (GWAS) strongly associated the rs613872 variant in TCF4 
with FECD.46 It was later discovered that this SNP was in linkage disequilibrium with 
CTG18.1, a CTG repeat expansion in the third intron of TCF4.47 CTG repeat expansions cause 
formation of nuclear RNA foci, these RNA foci act to sequester splicing factors such as 
MBNL1 and MBNL2; causing a deficiency of these proteins and missplicing of the TCF4 gene 
leading to FECD. 48,49 
1.3 The cornea as a target for genome engineering 
The cornea serves as an ideal tissue for genome engineering strategies. As previously described 
the corneal dystrophies are monogenic and present with a mendelian pattern of inheritance, 
allowing for the design of a gene-editing approach targeted to the single causative gene. In 
addition, it has a small surface area, therefore gene-editing can be localised reducing the 
number of cells in which editing must occur. Importantly, it is readily accessible and easily 
visualised, therefore both treatment and phenotypic readout can be performed in a routine 
manner. Finally, as the cornea is avascular it holds a unique immune privileged status. While 




also major restrictions. One of the primary functions of the cornea is to provide a structural 
barrier between the outside world and the eye. As such the cornea has many adaptations 
preventing entry of foreign substances, such as characteristically impermeable junctions, 
making delivery of gene therapy reagents to the corneal layers very challenging. Considerations 
for the delivery to the cornea are extensively discussed in Section 5 of Paper I. 
1.4 Overview of the CRISPR/Cas system 
Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/CRISPR associated (Cas) 
systems provide a tool to achieve targeted double strand breaks (DSB) within the genome, upon 
creation of a DSB the cell will initiate endogenous repair pathways to correct this damage and 
it is by these cellular responses that genome modifications can been achieved. CRISPR-Cas 
systems can be divided into two classes; Class I which require multiple effectors and Class II 
which only require a single effector protein50. These classes are then further divided into five 
different types based on the effector proteins present (Table 2). As Class II CRISPR systems 
only require a single effector protein they have been heavily utilised in genome engineering; 
Class II systems consist of type II in which the effector protein is Cas9 and type V in which 
the effector protein is Cas12a (formerly known as Cpf1). Employing these Class II systems to 
generate DSBs in mammalian cells only requires two-components, a Cas nuclease which 
recognises a specific DNA motif known as a protospacer adjacent motif (PAM) and a single 
guide RNA (sgRNA), the Cas nuclease and sgRNA will form a complex and scan the genome 
for suitable targets (Figure 7). Cas9 and Cas12a have become widespread tools across 





Figure 7: Cas9 (orange) scans the genome in search of a PAM (red), once a PAM is 
encountered it will determine if the 20bp guide sequence (dark green) is complementary to 
the sequence immediately adjacent to the PAM (light green), if there is adequate specificity 









Table 2: Current classification of known CRISPR  systems 
Class  Type Multi/single protein effector 
Class I 
Type I 
Multisubunit effector complex Type III 
Type IV 
Class 2 
Type II Single effector protein - Cas9 
Type V  Single effector protein - Cas12a 





1.5 Discovery of the CRISPR/Cas system as an adaptive immune response 
CRISPR repeats were first reported by a Japanese group in 198751, they had observed these 
repeat sequences in E.coli but had not considered their presence to be remarkable. While 
studying gene expression of Haloferax mediterranei in response to extreme salt concentration 
Francisco Mojica again found these repeat sequences52, which he reported to be multiple copies 
of palindromic, repeated sequence of 30 base pairs, separated by spacers of approximately 36 
base pairs. Interestingly, the spacer sequences were unlike any family of repeats previously 
characterised in microbes. He then began to discover these repeats in additional microbes 53, at 
this point Mojica recognised the significance of these repeats. Speaking in an interview with 
the CRISPR journal54, Mojica recalled “they are found in many distantly related prokaryotes. 
Some Archaea have 2% of their genome made up of these repeats, so that tells me this is really 
important.” He believed that in order to understand the function of the repeats, he had to 
understand the origin of the intervening spacers, as the spacers differ greatly between species. 
By 2000 Mojica had identified these repeat sequences in 20 different organisms55, which he 
had coined Short Regularly Spaced Repeats (SRSRs), SRSRs were later renamed to Clustered 
Regularly Interspaced Palindromic Repeats (CRISPR). Jansen et al reported the existence of 
CRISPR associated (cas) genes56, which were found to be invariably located adjacent to the 
CRISPR locus, indicating a common function. In an attempt to understand the identity of the 
spacer sequences Mojica BLASTed them one by one. In 2003, after many failed attempts, a 
spacer isolated from an Escherichia coli (E.coli) strain matched the sequence of a P1 phage. 
Critically, the E.coli strain that spacer was derived from is known to be resistant to P1 infection. 
Further investigation revealed that 2/3 of spacers with sequence matches corresponded to 
extrachromosomal plasmids and bacteriophages57, indicating CRISPR has a role as an adaptive 
immune system that can protect the bacteria against these elements. In parallel, Gilles 




to an inactive prophage within the Y.pestis genome58, leading to the same conclusion that 
CRISPR acted an adaptive immune system. At the same time Alexander Bolotin found that the 
resistance of Streptococcus thermophilus (S.thermophilus) to phage correlated with the number 
of spacers that were present and he also came to the conclusion that CRISPR acted as an 
adaptive immune system59. He also proposed that CRISPR suppressed these extrachromosomal 
elements by coding for anti-sense RNA. Three groups had now independently shown homology 
between the spacer sequences and foreign elements and were all proposing the CRISPR system 
to act as an adaptive immune system. Barrangou et al were the first to substantiate this 
hypothesis60; demonstrating that not only is the sequence similarity between the spacer and 
target used for recognition but that when polymorphisms between the spacer and target were 
present the bacteria would lose resistance. Furthermore, inactivation of cas7 did not affect 
resistance while inactivation of cas5 (now referred to cas9) resulted in a loss of resistance, 
hypothesising that cas5 (cas9) acts as a critical nuclease, supported by its previously reported 
RuvC and HNH nuclease domains 59,61.   
1.5.1 Reprogramming of CRISPR/Cas systems 
The first demonstration of reprogramming of a CRISPR/Cas system was using the Class I, type 
I CRISPR system from E.coli; Brouns et al reported that the CRISPR loci was transcribed into 
a pre-crRNA (precursor-crisprRNA), which was then cleaved to form a mature crRNA. 
Moreover, the crRNA together with the effector complex was responsible for cleaving the 
target sequence and finally utilising synthetic spacers targeted to lambda (λ) phage, resistance 
to λ phage was induced. By achieving resistance with both coding and non-coding spacers they 
were the first to hypothesise that CRISPR targeted DNA, challenging previous hypotheses that 
CRISPR worked by an anti-sense RNA mechanism. Further work again showed target 
similarity directs CRISPR activity but additionally provided confirmation that CRISPR 




complementary to the nickase (nes) gene, which is present in the majority of staphylococcal 
conjugative plasmids, CRISPR interference was used to prevent conjugation. Moreover, 
disruption of the nes spacer target site by the introduction a self-splicing intron, which after a 
splicing event would reform the target sequence, revealed that conjugation was not inhibited. 
This proved that when the target exists in the mRNA but not in the DNA, CRISPR does not 
function, therefore the system must act on DNA.  
1.5.2 Target recognition and cleavage 
Two papers identified an additional CRISPR element that indicated spacer acquisition was not 
random. An exact sequence motif was always located downstream of the protospacer63,64, now 
referred to as a protospacer adjacent motif (PAM). Furthermore, different Cas nucleases were 
shown to recognise unique PAMs. PAM recognition has since been extensively studied 
confirming that Cas nucleases isolated from different strains have distinct PAMs; such as 
Streptococcus pyogenes Cas9 (SpCas9) that recognises a NGG motif, Staphylococcus aureus 
Cas9 (SaCas9) that recognises NNGRRT, Acidaminococcus Cas12a (AsCas12a) and 
Lachnospiraceae bacterium Cas12a (LbCas12a) which both recognise a TTTN motif65–69. 
PAM sequences are critical recognition domains because they provide a mechanism for the 
Cas nuclease to discriminate between self and non-self DNA70. By sequencing the immediate 
products of Cas9 cleavage Garneau et al demonstrated that Cas9 creates a blunt double-strand 
break (DSB) in the target DNA and that this event always occurs 3bp upstream of the PAM71, 
demonstrating the precision of this tool at making targeted DSBs. In contrast Cas12a, the other 
Class II system that has been repurposed for genome engineering, was found to generate a 
staggered DSB with a 5’ overhang69. Deltcheva et al uncovered a novel small RNA that was 
transcribed from the region adjacent to the CRISPR locus, critically this transcript has a 24-
nucleotide complementarity to the repeat regions of pre-crRNA72. This trans-activating 




RNase III was processed into mature crRNA.  Sapranaukas et al showed that the CRISPR 
system from S.thermophilus could be transferred to E.coli were it retained its function to cleave 
both plasmid and viral DNA73. Importantly, they also demonstrated that the only protein 
necessary to maintain function was Cas9.  
1.5.3 Repurposing CRISPR/Cas9 for use in mammalian cells 
The fundamental components for the CRISPR system were now known, using purified Cas9 
and in vitro transcribed crRNA and tracrRNA Jinek et al showed that it was possible to 
reprogram the CRISPR system to cleave a target in vitro65. In addition, by mutating the catalytic 
domains of RuvC and HNH they confirmed RuvC cuts the strand complementary to the crRNA 
and HNH cut the strand non-complementary to the crRNA. Finally, in what would become a 
key aspect of genome editing by CRISPR systems, they demonstrated that the crRNA and 
tracrRNA could be fused to produce a single-guide RNA (sgRNA), negating the need for 
processing by RNase III. Gasiunas et al published work very parallel to this just weeks later74. 
Cong et al were the first to achieve gene-editing in mammalian cells using the CRISPR-Cas9 
system66. This was achieved by codon-optimising SpCas9 and attaching nuclear localization 
signals (NLS), this optimised SpCas9 together with an adopted version of the sgRNA described 
by Jinek et al, which again was a chimera of crRNA and tracrRNA but of different lengths, 
was both necessary and sufficient to achieve efficient gene editing. They also created a mutant 
nickase SpCas9 containing a previously described alanine substitution (D10A)65,73,75 in the 
RuvC domain. As this nickase would only result in a single strand DNA nick different DNA 
repair mechanisms will process it and thus different genomic modifications can be achieved. 
Finally, they demonstrated that it was possible to target multiple genes simultaneously by using 
a CRISPR array encoding several spacers. Published in the same issue of Science, Mali et al 
also showed a two-component CRISPR system achieved efficient edits in mammalian cells and 




nucleases have since been repurposed for use in mammalian cells68,69. These landmark papers 
by the labs of Doundna & Charpentier, Zhang and Church established CRISPR/Cas systems as 
a tool for mammalian gene-editing, however CRISPR was first reported in 1987 and it is only 
by the instrumental efforts of a large number of people that this feat has been achieved.  
1.6 DNA Repair related to a DSB 
The Cas nuclease employed generates a DSB within the cell, however it is by the DNA repair 
mechanisms initiated in response to the DSB by which genome editing can be achieved. It has 
been estimated that ~105 DNA lesions occur in the mammalian genome each day76, including 
DSBs, as such mammalian cells have various DNA repair mechanisms to deal with this 
damage. DSBs are considered the most lethal lesion in DNA, it is widely accepted that they are 
repaired by either homology directed repair (HDR) or non-homologous end joining (NHEJ) 
repair (Figure 8). Homologous recombination (HR) is only active during S and G2 phases of 
the cell cycle, therefore can only occur within dividing cells. Conversely, NHEJ occurs in both 
dividing and non-dividing cells.   
The exact mechanism behind repair of the blunt-ended DSB induced by Cas9 is unknown. 
Work is ongoing to elucidate the exact pathways implemented and thus how to manipulate 
them to make the genome modifications more favorable for the desired outcome. Generally, it 
is accepted that HR is a precise mode of repair, requiring a template in the form of a 
homologous chromosome or synthetic donor, that can be utilised to introduce specified 
changes. Synthetic donors typically include either a double-stranded oligonucleotide (dsODN) 
or single-stranded oligonucleotide (ssODN). Conversely, NHEJ is an error-prone repair 
pathway, in which ends of the DSB are joined together in an imperfect manner that results in 






Figure 8: Different modes of repair of a Cas9 induced DSB. DSBs are either repaired by 
NHEJ which induced indels that may lead to frameshifting mutations resulting in a premature 
stop codon, resulting in gene disruption. Alternatively the DSB is repaired by HR in which a 
template, either the homologous chromosome or a donor template, is used for repair. HR can 






can result in a premature stop codon, which provided it occurs ≥50-55 nucleotides upstream of 
the 3’ most exon-exon junction 77,78, can  cause gene disruption.  
Richardson et al recently published an interesting finding into HR in relation to a ssODN, 
which is referred to as single-stranded template repair (SSTR)79. Using a high-throughput 
screen they identified that the Fanconi Anaemia (FA) pathway, known to recognise and repair 
interstrand cross-links, was critical to SSTR but had no effect on NHEJ repair. However, using 
chromatin immunoprecipitation sequencing (ChIP-seq) they found that FANCD2, involved in 
the FA pathway, localizes to Cas9-induced DSBs, regardless of the presence of ssODN. They 
hypothesised that the FA pathway acts as a mediator to direct the repair pathway of the DSB. 
In the absence of a ssODN NHEJ will occur as normal, however in the presence of a ssODN 
HR by either standard HR, SSTR or single-strand annealing (SSA) can occur.  
Predominantly DSBs will be repaired by NHEJ, allowing efficient gene disruption. HDR 
provides a tool to correct a genetic defect or introduce new genetic information. However, HR 
is extremely inefficient therefore efforts have been focused on increasing the efficiency of this 
repair outcome to maximise its potential. As more insights into the exact mechanisms of Cas9 
DSB repair are made, potential strategies to increase HR may become apparent. 
1.7 Structure of sgRNA:Cas9 complex 
The crystal structures for inactive Cas9, a sgRNA:Cas9 complex and a sgRNA:Cas9 complex 
bound to target DNA have now been published80–83. The crystal structure of a sgRNA:Cas9 
complex bound to target DNA revealed that there are two lobes; a recognition lobe (REC) and 
a nuclease lobe (NUC)82. The REC lobe can be sub-divided into seperate domains including 
REC1, REC2 REC3 and an  bridging helix. While the NUC lobe can be sub-divided to contain 




heteroduplex that forms when the sgRNA binds to its target sequence is positioned in a positive 
groove between the REC and NUC lobes.  
1.8 Mechanism of cleavage by Cas9 
Broadly, target recognition by the sgRNA-Cas9 complex is thought to involve two main stages, 
the recognition of a suitable PAM and the formation of a RNA-DNA heteroduplex84. Initially 
S.pyogenes Cas9 will sample PAMs via the PAM interacting domain, following identification 
of a suitable NGG PAM the SpCas9 nuclease will then test the PAM-proximal sequence for 
complementarity with the guide sequence provided. If high sequence similarity exists SpCas9 
will then test the PAM-distal portion of the guide and if further complementarity exists SpCas9 
will then generate a DSB. Sternberg et al demonstrated that the conformational change of the 
HNH domain acts as an additional proofreading mechanism85. Indicating that a mechanism 
exists whereby Cas9 recognises a PAM and tests the adjacent sequence for complementarity, 
if an on-target sequence is identified this drives a conformational change within the HNH 
domain, which acts as a allosteric switch to trigger the RuvC domain and results in a concerted 
cleavage of both strands. Off-target sites are known to bind Cas9, however this explains why 
although mismatches allow Cas9 binding without a conformational change in the HNH domain, 
cleavage will not occur86. Further studies into the mechanism of Cas9 cleavage have revealed 
that HNH transitions between several conformations before docking into its active state, 
demonstrating that there is an intermediate state that governs transition of DNA binding and 
DNA cleavage by Cas9 87.  
1.9 Limitations of CRISPR/Cas9 
While CRISPR-Cas9 holds immense potential for the field of gene editing there are also a 
number of issues impeding the translation of this technology to the clinic. Firstly, SpCas9 is 




challenge. Delivery is a challenge faced throughout the field of gene therapy and is not 
exclusive to ocular gene therapy. However, each target tissue has their own unique barriers to 
be overcome in order to achieve potent and specific delivery to the cell of interest. The cornea 
exists as a structural barrier to prevent entry of foreign substances into the eye. As such, it has 
evolved to be difficult to penetrate. Adeno associated virus (AAV) has the ability to infect a 
range of cell types due to the receptors present on the AAV capsid. Different AAV serotypes 
have tropisms for different tissues due to the capsid proteins present on their surface. The 
payload of this widely used gene therapy vehicle is <5kb; the coding sequence of SpCas9 alone 
is 4.2kb, inclusion of additional components including sgRNA and promoters exceed the 5kb 
limit. In order to overcome this limitation several solutions have been explored, including, 
splitting the CRISPR components across two vectors and utilising SpCas9 orthologues smaller 
in size. Another issue is that AAV results in the sustained expression of the transgene, dual 
AAV systems that carry an additional guide designed to disrupt the transgene have been 
explored88–90. Furthermore non-viral delivery solutions that result in reduced expression of 
Cas9 within the cell have been investigated91,92. The Cas9 protein in complex with the sgRNA 
is highly anionic, thus the carriage of this large negatively complex across a cell membrane can 
be quite inefficient. The specific challenges associated with both delivery to the eye and 
delivery of CRISPR/Cas9 components are extensively discussed in Paper I section 5.  
Critically, it has been widely shown that SpCas9 can tolerate mismatches within the guide 
sequence leading to the generation of DSBs at sites with high sequence similarity to the guide 
sequence employed 93–95. These off-target events can occur at sites with several mismatches 
relative to the guide sequence anywhere within the genome. The inadequate genome-wide 
specificity of SpCas9 has fueled extensive research into ways to reduce off-target cleavage. 
Such as selecting guides that do not have high homology to other sites in the genome, thus 




been shown to confer greater specificity 96. Finally, several high fidelity SpCas9 variants have 
been engineered using rational design 97–99, these variants exhibit improved global specificity, 
however off-target events have not been completely eliminated. 
As the majority of the corneal dystrophies are due to missense mutations that present with an 
autosomal dominant inheritance pattern an allele-specific knockout of only the mutant allele 
would be a viable treatment approach for these dystrophies. When considering global 
specificity, it is extremely rare to encounter an off-target site that differs by only a single base 
pair. However, for allele-specific editing this off-target site will inevitably exist and will act as 
the most perilous off-target event, as unintended cleavage at the non-target allele will result in 
a loss of the functional protein and may exacerbate the disease. Thus, in order to develop a 
gene therapy for the corneal dystrophies the ability to distinguish between single base pair 
changes is paramount. 
1.10 Conclusion 
The unique qualities of the cornea and genetics of the corneal dystrophies make it an amenable 
target for gene therapy. The CRISPR technology holds vast potential to treat the corneal 
dystrophies. However, in order to realise this potential a number of issues must be overcome, 
specifically, efficient delivery to the cornea and both improved discrimination between wild-
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1.12 Thesis aims 
The overall aim of this thesis was to investigate the potential of treating autosomal dominant 
corneal dystrophies by CRISPR/Cas9, by inducing allele-specific gene disruption of only the 
mutant allele. This thesis aims to overcome the current limitations of the CRISPR/Cas9 system, 
to enable the treatment of the TGFBI corneal dystrophies.  
 
In fulfilment of this aim, the objectives of the research presented in this thesis were to: 
 Write a comprehensive review of the position of the corneal dystrophies in relation to 
genome editing 
 Investigate possible mechanisms of how TGFBI corneal dystrophy patients develop an 
accumulation of corneal deposits following laser eye surgery 
 Define the ability to target the TGFBI corneal dystrophy missense mutations utilising  
known allele-specific strategies  
 Explore the possibility of exploiting natural variation within the genome to achieve 
allele-specific editing 



















2 Paper I - Personalised genome editing – the future for corneal dystrophies 
C.B. Tara Moore*, Kathleen A. Christie*, John Marshall, M. Andrew Nesbit 
* These authors are co-first authors 
2.1 Aims and author contributions 
The main aim of this paper was to: 
1. Generate an informative review article collating relevant literature relating to the field 
of gene editing and discuss how recent advancements can be applied to the treatment 
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3 Paper II - Towards personalised allele-specific CRISPR gene editing 
to treat autosomal dominant disorders 
Kathleen A. Christie, David G. Courtney, Larry A. DeDionisio, Connie Chao Shern, 
Shyamsree De Majumdar, Laura C. Mairs, M. Andrew Nesbit, C.B.Tara Moore 
3.1 Aims and author contributions 
The main aims of this paper were to: 
1. Demonstrate gene disruption by NHEJ in vivo 
2. Determine what proportion of the TGFBI missense mutations could be targeted by an 
allele-specific CRISPR/Cas9 targeting approach 
3. Compare a PAM-specific approach and guide-specific approach and determine which 
confers more stringent allele-specificity when targeted to single base pair mutations 




For this manuscript I performed the mutational analysis of the 62 TGFBI missense mutations. 
I cloned all plasmid constructs and generated all cleavage templates used throughout. I 
performed all dual-luciferase assays and in vitro digests. I formed a collaboration with Prof 



















































































4 Paper III - ASNIP-CRISPR enables mutation independent allele-specific editing 
by Cas9 
Kathleen A. Christie, Kevin Blighe, Marie Lukkassen, Zaheer Ali, Larry A. DeDionisio, Caroline 
Conway, Anton Lennikov, Connie Chao Shern, Rachelle E. Irwin, Doug Turnbull, John Marshall, Jan 
J. Enghild, Lasse D. Jensen, M. Andrew Nesbit, C.B.Tara Moore* 
 
4.1 Aims and author contributions 
The main aims of this paper were to:  author  
1. Determine if TGFBIp has a role in wound healing via a tail-fin regeneration assay 
2. Identify SNPs with a MAF of >0.1 that have a PAM present on only one allele 
3. Estimate the proportion of the East Asian population that could be targeted by ASNIP CRISPR 
utilising the SNPs identified in aim 2 
4. Perform phased sequencing in a R124H TGFBI corneal dystrophy patient, determine if the 
patient has any of the SNPs identified in aim 2 and if they contain a novel PAM on the same 
allele as the mutation 
5. Design guides utilising SNPs within the R124H patient genome that match the above criteria 
6. Determine if these guides can achieve allele-specificity in an in vitro digest and in a patient 
derived lymphocyte cell line 
7. Demonstrate the potential of generating an allele-specific dual-cut 
 
Contribution 
I formed a collaborator with Dr Lasse Jensen and travelled to Sweden to carry out the tail-fin 
regeneration assay. I performed mutational analysis on the TGFBI locus to identify SNPs with a MAF 
of >0.1. Using haplotype data from the 1000 Genomes I calculated the proportion of the East Asian 
population that could be targeted by this approach. I designed guides utilising the phased sequencing 
data. I generated a lymphocyte cell line by EBV transformation of PBMCs which I isolated from the 
whole blood of the R124H patient. I tested these guides in in vitro digests and performed all single and 
dual nucleofections. I extracted DNA and performed all PCR and qPCR reactions. I wrote the 
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Abstract  
Corneal dystrophies are predominantly caused by autosomal dominant missense mutations. 
Silencing only the mutant allele offers a promising treatment strategy for these blinding 
diseases. Gene disruption by CRISPR/Cas9 provides a tool to permanently silence the mutant 
allele. In order to discriminate between wild-type and mutant alleles Cas9 must be able to 
detect a single base pair change. Allele-specific editing can be achieved by employing either 
a guide-specific approach, in which the missense mutation is found within the guide 
sequence; or a PAM-specific approach, in which the missense mutation generates a novel 
PAM. While both approaches have been shown to offer allele-specificity in certain contexts, 
in cases where a number of missense mutations are associated with a particular disease, such 




individually. Here we demonstrate allele-specific, SNP-derived PAM, in cis, personalised 
(ASNIP) CRISPR is capable of achieving complete allele discrimination and propose it as a 
targeting approach for autosomal dominant disease. ASNIP CRISPR utilises natural variants 
in the target region that contain a PAM on one allele which lies in cis with the causative 
mutation. Consequently, the targeting approach is no longer constrained by the mutation, 
ensuring a highly specific guide can be selected. In addition, genetic variation has been 
shown to affect the target specificity of CRISPR. ASNIP CRISPR guide design will take into 
account the patient’s individual genetic make-up allowing on and off target activity to be 
assessed in a personalised manner. 
Introduction 
Corneal dystrophies comprise a group of inherited, bilateral genetic eye diseases that affect 
the transparency or shape of the cornea, which can lead to progressive vision loss and 
eventually blindness1. Transforming growth factor β-induced (TGFBI) has been implicated as 
the causative gene in a number of epithelial and stromal corneal dystrophies.  TGFBIp is an 
extracellular matrix (ECM) protein and through its interaction with integrins is involved in 
many key cellular processes, thus has been shown to have a role in wound healing, 
angiogenesis, cancer and inflammatory diseases2,3. Despite the fact that TGFBIp is 
ubiquitously expressed, mutations within TGFBI appear only to result in an adverse 
phenotype in the cornea, although the mechanism behind the accumulation of mutant 
TGFBIp in the cornea is incompletely understood. To date >60 different disease-causing 
missense mutations within TGFBI have been described; these mutations and the dystrophies 
associated with them are broadly known as TGFBI  corneal dystrophies4,5. A very strong 
genotype-phenotype correlation exists between each missense mutation and the pattern of the 
mutant protein deposits that accumulate in the cornea. They are monogenic and are 




amenable to gene replacement therapy, as the production of mutant protein in the cornea will 
persist. Repair of the R124H missense mutation has been demonstrated in patient-derived 
primary corneal keratocytes6. However, template repair is considered relatively rare in most 
cell types7. Critically, patients that have an underlying TGFBI mutation but a seemingly quiet 
cornea who receive laser eye surgery will see a sudden emergence of corneal opacities 2,8–11, 
indicating a potential role for TGFBI in wound repair, suggesting complete knockout of 
TGBFI in the cornea would not be advisable. Due to the autosomal dominant inheritance 
pattern of the TGFBI corneal dystrophies selective ablation of only the mutant allele may be a 
viable treatment strategy. Heterozygous nonsense mutations in TGFBI associated with a 
normal phenotype have been reported12,13, indicating that TGFBI is haplosufficient and 
disruption of only the mutant allele would not lead to a more severe phenotype. Allele-
specific siRNAs targeted to a lattice corneal dystrophy (LCD1) (OMIM:122200) mutation 
R124C have been shown to achieve potent and specific knockdown of the mutant allele14. 
However, as knockdown of mutant protein expression by siRNA is only transient and would 
require continued application and, depending on the delivery route chosen, likely repeat 
injections into the eye, permanent disruption of the mutant allele would be an attractive 
alternative strategy. Non-homologous end-joining (NHEJ) mediated gene disruption by 
CRISPR/Cas9 provides a tool to permanently silence a gene 15. S.pyogenes Cas9 searches the 
genome for a NGG protospacer adjacent motif (PAM), once a NGG PAM is encountered 
Cas9 will determine if the guide sequence supplied has complementarity with the flanking 
sequence. If there is global sequence similarity Cas9 will bind and generate a double-strand 
break (DSB) at this location. NHEJ, the DNA repair mechanism most often used in non-
dividing cells, can introduce insertions and deletions (indels) at the repair site and can result 
in a frameshifting mutation leading to premature termination of translation and thus 




caused by single base pair changes, therefore to achieve allele-specific NHEJ mediated gene 
disruption of mutant TGFBI, Cas9 must be able to discriminate between wild-type and 
mutant alleles which differ by only a single base pair change. Allele-specific editing of 
missense mutations via CRISPR/Cas9 can be achieved by employing either a guide-specific 
approach, in which the missense mutation is found within the guide sequence; or a PAM 
specific approach, in which the missense mutation generates a novel PAM. Utilising a guide-
specific approach has been shown to be promising, achieving good allele discrimination with 
certain mutations16–18. However, successful application of this approach requires the mutation 
of interest to have a usable PAM in close proximity, in addition to having a flanking guide 
sequence that has both a good on and off target cleavage profile. The position of the missense 
mutation within the guide sequence, and critically within the seed region, which is defined as 
the first 8-12nt in the guide sequence, has been shown to limit this approach, with a reduction 
in the allele discrimination observed the more distal the mutation is from the PAM19. 
Similarly, while exploitation of a novel PAM has been shown to confer stringent allele-
specificity15,20, only a fraction of missense mutations will generate a novel PAM19. While 
both approaches can be efficiently utilised in the context of certain mutations, they both 
highlight the limitations of a mutation dependent approach. In the case of TGFBI corneal 
dystrophies, >60 missense mutations are currently associated with disease, utilising either a 
guide-specific or PAM specific approach would require the design of >60 different guides 
that all have good on-target activity and low off-target activity, which is an insurmountable 
task as >1/3 of these missense mutations cannot be targeted by either approach and not all of 
the remaining mutations will offer guides with good on and off target profiles19. Here we 
demonstrate that allele-specific, SNP-derived PAM, in cis, personalised (ASNIP) CRISPR is 
capable of achieving stringent allele discrimination with wild-type S.pyogenes Cas9 and 




independently of the mutation present. We present a work flow that allows allele-specificity 
to be achieved in cases where phase cannot be pre-determined21. ASNIP CRISPR utilises 
natural variants in the target region that are associated with a PAM on only allele that lie in 
cis with the causative mutation (supplementary figure 2). Consequently, the targeting 
approach is no longer constrained by the mutation. While employing common variants 
ensures that a pool of well tested guides can be used to treat the majority of individuals in a 
given population. Genetic variation has been shown to affect the target specificity of 
CRISPR22,23, we present a workflow for genes associated with autosomal dominant disease 
that will allow guide design based on the patient’s individual genetic make-up, therefore on 
and off target activity can be routinely assessed, in a personalised manner for every 
therapeutic application. 
Materials and Methods 
Caudal fin regeneration assay 
Zebrafish were housed under standard conditions24 at the Linköping University Zebrafish 
Core Facility. For caudal fin amputations, fish were anesthetized in 0.02 % tricaine and fins 
were cut using scalpel blades, care was taken to cut perpendicular to the anterior/posterior 
plane of the animal. 3 days post amputation fish were were anesthetized in 0.02 % tricaine 
and 3 nmole/ul morpholino 5’-GAGACGCATTGGGAACTCACAGTGG -3’ (Gene Tools) 
was mixed with rhodamine red 1 ug/ul at ratio 9:1, was injected distal to each bone ray along 
the regenerating tissue on the dorsal side of the fin. Immediately following injection each side 
of the fin was electroporated using a 3 mm diameter tweezer electrode (BTX, Holliston, MA, 
USA) and electroporator (BTX, Holliston, MA, USA) the parameters used were ten 
consecutive 50 msec pulses, at 15 V with a 1 sec pause between pulses. 5 days post injection 




collected for LC-MS/MS. These studies were approved by the Linköping Research Animal 
Ethical Council. 
LC-MS/MS of regenerated caudal fins 
The regenerated caudal fins from seven fish were collected and separated into morpholino 
treated and untreated halves.  Each sample was incubated in 8 M urea, 100 mM ammonium 
bicarbonate, pH 8 for 1h at room temperature.  The samples were then reduced with 5 mM 
DTT for 30 min followed by alkylation with 25 mM iodoacetamide (IAA) for 30 min. 
Remaining IAA was quenched with 30 mM DTT and the sample diluted to 1 M Urea before 
addition of 2.5 μg trypsin. Digestion with trypsin was carried out O.N. at 37 °C. The digested 
samples were centrifuged (5 min, 17,000 ×g) before collection of 20 μl or 30 μl from 
untreated and treated samples respectively.  These aliquots were desalted on homemade 
reversed-phase micro columns containing small plugs of Octadecyl C18 Solid Phase 
Extraction disks (Empore, 3M) and dissolved in 10 μl 0.1% formic acid (solvent A) before 
LC-MS/MS analysis. Nano-LC-MS/MS analyses were performed on an EASY-nLC II 
system (Thermo Scientific) connected to a Q Excative Plus mass spectrometer (ThermoFisher 
Scientific). The samples were injected and desalted on a trap column (2 cm × 75 μm inner 
diameter) and separated on an in-house pulled silica emitter (15 cm × 75 μm inner diameter). 
Both columns were packed with PreproSil-Pur C18-AQ 3 μm resin (Dr. Maisch GmbH, 
Ammerbuch-Entringen, Germany).  The peptides were electrosprayed into the mass 
spectrometer by gradients from 5% solvent A to 35% solvent B (90% acetonitrile in 0.1% 
formic acid) over 50 min, followed by a quick increase to 100% solvent B over 10 min at a 
constant flow rate of 250 nl/min. Parallel reaction monitoring (PRM) analyses were 
performed in the targeted MS/MS mode, using Xcalibur software, with time-scheduled 
acquisition of the 12 peptides in +/- 5 min retention time windows (Supplementary Table 1) 




150 ms. MS/MS scans were acquired at a resolution of 35,000 at m/z 200. A full mass 
spectrum followed after every 50 PRM scans using the following parameters: resolution of 
70,000 at m/z 200, AGC target 3e6, m/z 250-2000, and maximum injection time of 200 ms.   
Quantification of MS Data.  
The raw files were converted to MGF files using RawConverter 25 and searched against 
zebrafish proteome (TrEMBL, and Swiss-Prot) using the Mascot search engine with the 
following parameters: MS tolerance of 10 ppm, MS/MS tolerance of 0.1 Da, trypsin with one 
missed cleavage, carbamidomethyl as fixed modification, and oxidized methionine as 
variable modification. One TGFBIp peptide was not identified and was excluded from the 
analysis. The raw files from the LC-MS/MS analysis were analysed in Skyline 26 and the 
extracted ion chromatograms (XIC) of three fragments of each peptide were extracted. The 
summed XIC of the eight TGFBIp peptides were normalized to the summed XIC of the three 
B-actin peptides. The significance of the results was tested by a two-tailed paired T-test. 
Phased sequencing of R124H patient genome 
Genomic DNA was extracted from 3 mls of whole blood with a MagAttract HMW DNA kit 
(QIAGEN, Hilden, Germany). DNA fragment lengths of approximately 45 kb were enriched 
for on a Blue Pippen pulsed field electrophoresis instrument (Sage Science, Beverly, MA, 
USA).  Fragment sizes averaging 51,802 bps were confirmed with a Large Fragment kit on 
the Fragment Analyzer (Advanced Analytical, Ankeny, IA, USA).  This high molecular 
weight (HMW) DNA (1 ng) was partitioned across approximately 1 million synthetic 
barcodes (GEMs) on a microfluidic Genome Chip with A Chromium™ System (10x 
Genomics, Pleasanton, CA, USA) according to the manufacturer’s protocol. Upon dissolution 
of the Genome Gel Bead in the GEM, HMW DNA fragments with 16-bp 10x Barcodes along 




according to the manufacturer’s instructions resulting in sample-indexed libraries using 10x 
Genomics adaptors. Prior to Illumina bridge amplification and sequencing, the libraries were 
analyzed on the Fragment Analyzer with the high sensitivity NGS kit.  One lane of whole 
genome paired end short read (2 x 150 nt) sequencing was conducted on a HiSeq 4000 
(Illumina, San Diego, CA, USA).  The FASTQ files served as input into Long Ranger (10x 
Genomics) which was used to assemble, align and give haplotype phasing information. 
TGFBI linkage disequilibrium analysis 
Chromosome 5 1000 Genomes27 Phase III data  in gzipped variant call format (VCF)28 for 
build GRCh37 / hg19 was downloaded from the Department of Biostatistics at the University 
of Washington in November 2014. Indels were left-aligned, multi-allelic calls split, and the 
data converted to binary call format (BCF) using BCFtools v1.3.129. Variants spanning 
TGFBI (+/-1Kbp) were then extracted, also using BCFtools. The resulting dataset was then 
temporarily converted to plaint-text VCF to allow for the manual recoding of rs11348106 (a 
variant of interest) from an indel variant to a dummy single nucleotide variant to allow for 
later compatibility with downstream tools, before being converted back to BCF. From this 
dataset, sample groups were then extracted into separate BCF files for the following 1000 
Genomes populations: CHB - Han Chinese in Beijing, China (n=103), EAS - East Asian 
super population (n=504), JPT - Japanese in Tokyo, Japan (n=104). Each file representing 
each population was then converted into a separate PLINK dataset using PLINK 
v1.90b3.3830. From PLINK, each dataset was then recoded into HaploView-compatible 
format using the options --chr 5 --from-bp 135364584 --to-bp 135399507 --snps-only no-DI –
recodeHV. Recoded datasets (as PED files) were then read separately into HaploView v4.231 
with default parameters: ignoring pairwise comparisons of markers > 500 Kbp apart; 
excluding individuals with > 50% missing genotypes. Within HaploView, from the ‘Check 




PNG format for each dataset from the ‘LD Plot’ tab. Colour scheme and numerical values for 
display were both set to ’R-squared’. The default method for identifying haploblocks, i.e., 
confidence intervals32, was used. The different haplotypes for each identified haploblock 
were then output in PNG format from the ‘Haploblocks’ tab. Again, default parameters were 
used: only including haplotypes > 1%; connecting with thin lines if > 1%; connecting with 
thick lines if > 10%. All subsequent figure editing was performed using GNU Image 
Manipulation Program v2.8.16 and R Programming Language 3.5.1. 
In vitro digestion to determine on-target specificity 
A double-stranded DNA template was prepared by amplifying a region of the luciferase 
reporter plasmid containing the desired sequence using the primers listed in Supplementary 
Table 2. A cleavage reaction was set up by incubating 30nM S.pyogenes Cas9 nuclease (NEB 
UK) with 30nM synthetic sgRNA (Synthego) for 10 minutes at 25˚C. The Cas9:sgRNA 
complex was then incubated with 3nM of DNA template at 37˚C for 1 hour. Fragment 
analysis was then carried out on a 1% agarose gel. 
Preparation of primary human PBMCs 
A whole blood sample was collected from a patient with Avellino corneal dystrophy. PBMCs 
were isolated by centrifugation on a Ficoll density gradient. PBMCs were washed in RPMI 
1640 media containing 20% FBS and incubated with EBV at 37˚C for 1 hour. After infection 
RPMI 1640 containing 20% FBS was added to a total volume of 3ml and 40µl of 1mg/ml 
phytohaemagglutinin was added. 1.5ml of the lymphocyte mixture was added to two wells of 
a 24-well plate and allowed to aggregate. Lymphoblastoids were cultured in RPMI 1640 
media containing 20% FBS. 




S.pyogenes Cas9 nuclease (NEB) and modified synthetic sgRNAs (Synthego) were 
complexed to form RNPs. RNPs were formed directly in the Lonza Nucleofector SF solution 
(SF Cell line 4D‐Nucleofector X kit - Lonza), and incubated for 10 minutes at room 
temperature. Desired number of cells were spun down (300g x 5mins) and resuspended in 
Nucleofector solution. 5µl of each cell solution was added to 25µL of corresponding 
preformed RNPs, mixed and transferred to the nucleofector 16‐well strip. The cells were 
electroporated using the 4D Nucleofector (Lonza) and program DN-100, cells were allowed 
to recover at room temperature for 5mins and 70µl of pre‐warmed media was added to each 
well of Lonza strip to help recovery. The transfected cells were then transferred to 24‐well 
plate with 200µl media. After 48hrs of incubation at 37°C, gDNA was extracted using the 
QIAmp DNA Mini Kit (Qiagen), the target region was PCR amplified using primer pairs 
listed in Supplementary Table 2 and targeted resequencing was performed. 
Targeted resequencing across target locus 
48 hours post nucleofection gDNA was extracted from cells and PCR amplified using primer 
pairs listed in Supplementary Table 2. PCR products were purified using the Wizard® PCR 
Preps DNA Purification System (Promega)and subjected to TruSeq PCR free library 
preparation. Samples then underwent paired end sequencing using an Illumina MiSeq 
instrument as per the manufacturer’s instructions. For genomic DNA samples, paired FASTQ 
files first undewent read filtration and trimming with Trim Galore! V0.4.0 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) (utilising Cutadapt v1.15 
and FastQC v0.11.5), using default parameters and --qual 20 --length 70 –paired. Reads from 
human samples were then aligned to the reference genome GRCh38 / hg38 / 
GCA_000001405.15 (downloaded from the UCSC), using BWA v0.7.12 (mem algorithm 
with default settings) 34. Aligned reads in SAM format were converted to BAM, sorted, and 




(https://broadinstitute.github.io/picard/) and then expunged with SAMtools view function 
with parameter -F set to 0x400. Reads with MAPQ below 30 were also expunged using 
SAMtools view with parameter -q set to 30. Output BAMs were then sorted and indexed 
using SAMtools. Reads in each sample’s BAM file were then split based on the SNP of 
interest. This was achieved using SAMtools view to first extract reads overlapping the target 
SNP region, and then dividing these into allele-specific reads by using the shell function grep 
-e to extract reads containing each SNP of interest flanked by 3 bases in both the 3’ and 5’ 
directions. Allele-specificity of the resulting reads was visually checked for each sample in 
IGV v2.3.97 (http://www.broadinstitute.org/igv). The number of properly-paired reads in 
each allele-specific BAM file with and without indels was then tabulated by using SAMtools 
view in combination with the shell function awk to filter on the CIGAR string. For example: 
Reads with indels: samtools view -f 0x02 Allele1.BAM | awk '$6 ~ "I|D"', reads with no 
indels: samtools view -f 0x02 Allele2.BAM | awk '$6 !~ "I|D"'. Separately, for each allele-
specific BAM file, pindel v0.2.5b9 35 was used to identify indels and substitutions using 
default settings. Output for each input file was then converted to VCF using pindel2vcf with 
default parameters plus --min_coverage 1 --het_cutoff 0.1 --hom_cutoff 0.9 to allow for low 
frequency variants to be retained. Output VCFs were bg-zipped and tab-indexed, and then 
BCFtools was used to filter out variants that did not have any genotype call by using 
BCFtools view function with --exclude-uncalled –min-ac=1. 
Quantitative PCR 
RT-qPCRs were performed using 1× LightCycler 480 SYBR Green I Master (Roche), 10 μM 
primers and 10ng gDNA. Reactions were run on the LightCycler 480 II (Roche), with an 
initial incubation step of 95°C, 10 minutes; followed by 45 cycles of 95°C for 10 seconds, 
60°C for 10 seconds and 72°C for 10 seconds. Expression was normalised to β-actin, and 






Role of Tgfbi in zebrafish regenerating tail fin 
To test the hypothesis that TGFBIp is involved in wound healing a well-established zebrafish 
tail fin regeneration assay, commonly used to assess wound healing, was implemented 
(Figure 1a)36,37. 3 days post amputation (dpa) the dorsal side of the fin was injected with a 
morpholino targeted to tgfbi, mixed with rhodamine red, and five days later (8 dpa) fin 
regeneration of the tgfbi morpholino injected dorsal side was compared to the uninjected 
ventral side. For all fins assessed, the dorsal Tgfbi morpholino-injected side of the fin 
regenerated slower than the uninjected ventral side. On average there was a 55.50% (± 
5.52%) reduction in regenerating tissue of the Tgfbi morpholino-injected side when 
compared to the untreated, p <0.0001. (Figure 1b). Knockdown of Tgfbi protein in injected 
tail fins was confirmed by liquid chromatography mass-spectrometry (LC-MS/MS), with a 
25% decrease in Tgfbi protein between Tgfbi morpholino injected and control fins, p = 
0.0016 (Figure 1c). The reduction of wound repair associated with loss of Tgfbi protein 
indicates an essential role of TGFBIp in wound repair and suggests maintenance of wild-type 
TGFBIp in the cornea is required to maintain normal repair responses. Therefore, complete 
knockout of TGFBI would be detrimental should the cornea be injured. Thus, allele-specific 
gene disruption is necessary, in which only the mutant allele is targeted for disruption, 
leaving the wild-type allele intact. 
Identification of mutation-independent PAM-associated SNPS in the TGFBI Gene 
The TGFBI gene, including untranslated regions (UTRs) and introns, covers ~35kb, and there 
are 17 coding exons. Mutations within TGFBI occur in exons 4-16 but are clustered in 




mutations were analysed to determine if they were targetable for allele-specific NHEJ gene 
disruption by either a guide-specific or PAM specific approach utilising S.pyogenes Cas9; 
>1/3 were not targetable by either approach, in addition stringent allele-specificity could not 
be achieved for the 5 most prevalent mutations using a guide-specific approach, the 
specificity of Cas9 for the mutant allele varied for each mutation investigated and was 
dependent upon the position of the mutation in the guide sequence 19. Thus the feasibility of 
an alternative mutation-independent strategy was explored; it was hypothesised that allele-
specific targeting could be achieved by targeting non-disease causing SNPs that contain a 
PAM on only one allele, that lie in cis with the disease causing mutation. This approach was 
named allele-specific SNP-derived-PAM in cis personalised (ASNIP)CRISPR. To identify 
variants across the TGFBI locus suitable for the ASNIP-CRISPR approach, SNPs were 
filtered to keep those with a minor allele frequency (MAF) of > 0.1 across all of the 
individuals in the 1000 Genomes Project Phase 3 cohort, the remaining SNPs were then 
manually examined to determine which contain a PAM on only one allele. (Supplementary 
Figure 2a and Supplementary Table 3). If no suitable SNPs containing a PAM on only one 
allele, that lies in cis with the patient’s mutation, are found across the coding region of 
TGFBI it may be necessary to utilise SNPs outside in the flanking regions of TGFBI. In the 
case of TGFBI there are no genes within a 50kb region both upstream and downstream, 
allowing SNPs to be utilised in these regions without disrupting flanking genes, if necessary. 
(Supplementary Figure 2b). 
Haplotype Analysis of identified ASNIP SNPs across TGFBI 
Granular corneal dystrophy type II (GCD2), commonly known as Avellino corneal dystrophy 
(OMIM: 607541), is extremely prevalent in East Asia, in the Korean population the 
prevalence is 1 in 870 people affected, while in China the reported prevalence is 1 in 400 




frequencies across all populations are suitable for the populations in which TGFBI corneal 
dystrophies are prevalent we performed haplotype analysis using the 1000 Genomes project 
phase 3 data for the East Asian population (EAS) (Figure 2a,d) in addition to sub-populations 
of Han Chinese in Beijing, China (CHB) (Figure 2b,e) and Japanese in Tokyo, Japan (JPT) 
(Figure 2c,f), all based on the 24 SNPs that contain a PAM on only one allele in the coding 
region of TGFBI, highlighted in red on Supplementary Table 3. 3 Linkage disequilibrium 
(LD) blocks were found in the 1000 Genomes EAS population; the first block (EAS-B1) 
spans 1kb within intron 1-2 (rs2237063- rs756462), the second block (EAS-B2) spans 21kb 
from intron 2-3 (rs11738979) to intron 13-14 (rs10064478) and finally the third block (EAS-
B3) spans 1kb from intron 14-15 (rs6880837) to intron 15-16 (rs6865463) (Figure 2a). The 
recombination frequencies were 0.73 between EAS-B1 and EAS-B2, and 0.85 between EAS-
B2 and EAS-B3, 3 haplotypes exist for EAS-B1, EAS-B2 and EAS-B3 which account for 
100%, 98.3% and 99.9% of the haplotype frequencies for each block, respectively (Figure 
2d). The same pattern of 3 LD blocks was found in the 1000 Genomes CHB population; the 
first block (CHB-B1) spans 1kb within intron 1-2 (rs2237063- rs756462), the second block 
(CHB-B2) spans 21kb from intron 2-3 (rs11738979) to intron 13-14 (rs10064478) and finally 
the third block (CHB-B3) spans 1kb from intron 14-15 (rs6880837) to intron 15-16 
(rs6865463) (Figure 2b). The recombination frequencies were 0.80 between CHB-B1 and 
CHB-B2, and 0.81 between CHB-B2 and CHB-B3, 3 haplotypes exist for CHB-B1 and 
CHB-B3, while 4 haplotypes exist for CHB-B2, which account for 100%, 98.6% and 100% 
of the haplotype frequencies for each block, respectively (Figure 2e). 2 LD blocks were found 
in the 1000 Genomes JPT population; the first block spans 25kb from intron 1-2 (rs2237063) 
to intron 10-11 (rs6860369) and the second block spans 2kb from intron 13-14 (rs6880837) to 
intron 15-16 (rs6865463) (Figure 2c). The recombination frequency was 0.91 between JPT-




account for 99.1% and 99.4% of the haplotype frequencies for each block, respectively 
(Figure 2f). Of the 62 missense TGFBI mutations known to date 61/62 occur between exons 4 
and 14 (Figure 2), therefore for both EAS and CHB blocks 1 and 2 will span 61/62 known 
mutations, while for JPT blocks 1 and 2 will span <50% of all known mutations. 
The haplotypes identified were then analysed using only the large haploblock (EAS-B2, 
CHB-B2, JPT-B1) to determine the approximate % of the population in which ASNIP 
CRISPR could be used to selectively disrupt only one allele. ASNIP CRISPR relies on 
variation across the target locus therefore the % of homozygotes in the population were 
calculated as these portions of the populations are instantly not targetable. Considering only 
the allele frequencies of block 2 from figure 2d,e,f the percentage of homozygous individuals 
was calculated for each population using the Hardy-Weinberg equation for multiple alleles; 
after exclusion of the homozygous individuals it was calculated that 66% of the EAS 
population are heterozygous for these alleles and therefore potentially targetable, while 67% 
of the CHB population and 71% of the JPT population are potentially targetable. Critically, 
this analysis was performed using one large haploblock in each population, individuals who 
are homozygous for this haploblock may not be homozygous for the remaining haploblocks, 
therefore the % of the population that is potentially targetable may be underestimated. The 
different combinations of haplotypes were then assessed for targeting capacity (Figure 
Supplementary Figure 3); the number of targetable SNPs in each allele was determined 
(Supplementary Figure 3a,b,c) and then all possible heterozygous combinations for block 2 
were assessed to determine the targeting capacity of the heterozygous individuals in each 
population (Supplementary Figure 3 d,e,f). In the EAS population the fraction of the SNPs in 
block 2 that can be targeted across the different combination of heterozygotes ranges from 8 
to 18/19 (Supplementary Figure 3d), 5 to 17/19 in CHB (Supplementary Figure 3e) and 2 to 




considering haploblock 2 ASNIP CRISPR has the potential to target, for at least one position, 
all heterozygous combinations across all populations investigated, indicating that the 24 
SNPs identified can be used to treat the majority of East Asian patients. 
Guide design based on patient haplotype 
In order to validate this approach in a real-life example we performed phased sequencing of a 
Japanese patient harbouring a R124H TGFBI mutation causative of granular corneal 
dystrophy type II (GCD2), also known as Avellino corneal dystrophy (OMIM: 607541), the 
phased sequencing revealed the R124H patient had JPT-B1H1 which co-segregated with 
JPT-B2H1 and JPT-B1H2 which co-segregated with JPT-B2H2, differing by one position in 
JPT-B1H1 as the patient was homozygous for the major allele (Figure 3a); this allowed 
identification of SNPs associated with a PAM on only one allele that lie in cis with the 
patient’s R124H mutation. (Figure 3b, Supplementary Table 4).  Based on the phased 
sequencing results a range of guides targeted to the mutant allele were then designed. (Figure 
4a, Supplementary Table 5). The ability of wild-type S.pyogenes Cas9 to distinguish between 
‘PAM associated’ and ‘No PAM present’ alleles was assessed firstly by in vitro digestion 
(Figure 4b); a PCR product containing either the allele associated with a PAM or the allele 
with no PAM present was incubated with ribonucleoprotein (RNP) complexes of Cas9 and 
sgRNA, digestion products were then electrophoresed on an agarose gel and intensity of the 
digested products revealed the in vitro specificity of each guide. Of the 12 ASNIP guides 
tested, 8 appeared to preferentially cleave the PAM associated allele while 4 appeared to have 
little activity at either the ‘PAM associated’ or ‘No PAM’ allele. We found that SNPs 
generating a non-canonical PAM, which is a PAM sequence other than NGG that can still act 
as a weak PAM for S.pyogenes Cas9 such as NAG or NGA 39,40, on the ‘No PAM present’ 




to achieve stringent allele-specificity a SNP in which the allele not associated with a PAM is 
either NGC, NCG, NGT or NTG should be selected. 
Allele-specificity of single ASNIP guides in R124H lymphocyte cell line 
In order to generate a model to test the ASNIP CRISPR approach we generated a 
proliferating lymphocyte cell line (LCL) utilising peripheral blood mononuclear cells 
(PBMC’s) from the patient harbouring the TGFBI R124H mutation on which phased 
sequencing had been performed. RNP complexes of Cas9 and 9 modified synthetic sgRNAs, 
of the ASNIP guides previously tested in the in vitro digestion, were individually 
nucleofected into the R124H LCLs. To determine the allele-specificity of each ASNIP guide 
targeted resequencing across the on-target region, where Cas9 is predicted to cleave, was 
performed. The target region for all 9 guides was amplified and subjected to deep sequencing, 
and computational analysis was performed to determine the indels that had occurred and with 
which allele they were associated. For all ASNIP guides screened, we found that they could 
all efficiently distinguish between ‘PAM associated’ and ‘No PAM present’ alleles (Figure 
5a). On average only 3.7% of indels occurred on the allele not associated with a PAM, in 
comparison to 96.3% of indels on the allele that is associated with a PAM. Indicting that 
ASNIP CRISPR design can achieve stringent allele-specificity in a mutation-independent 
manner. However, in contrast to what was observed via the in vitro digest (Figure 4b), SNPs 
for which the ‘No PAM’ allele contained a known non-canonical PAM did not have reduced 
specificity compared to SNPs in which a known non-canonical PAM was not present on the 
‘No PAM’ allele, indicating that the in vitro screen can merely be used as a predictive tool for 
specificity but no strong conclusions can be drawn. In addition, ASNIP guide rs6860369 
appeared inactive in the in vitro screen but was active in a cellular context. For 8 out 9 
ASNIP guides tested the predominant indels observed were 1 or 2bp insertions, which 




Increasing distance between dual-guides reduces the efficiency of a productive edit 
ASNIP CRISPR provides an approach that removes the limitations of a mutation-dependent 
approach. All of the non-disease causing SNPs matching the ASNIP criteria were located in 
intronic regions, thus indels introduced by the single ASNIP guides do not have therapeutic 
potential. To overcome this an in cis dual-guide approach targeted to the mutant allele is 
required. Using phasing information, dual guides in cis with the mutation were designed to 
flank the coding region of TGFBI. The ASNIP approach allows the design of guides targeting 
any region of the gene, they are not constrained by the location of the mutation and, upon 
careful design, excision of the exons between the guides will result in a frameshift that will 
result in premature termination of translation and nonsense mediated decay (NMD) of the 
resultant mRNA and selective knockout of expression of the mutant allele. In order to reach a 
therapeutic threshold in vivo we must be able to excise the region between the dual-guides at 
a high frequency, however, the minimum reduction of TGFBIp in the cornea required to 
achieve a therapeutic effect is unknown. To our knowledge the maximum distance possible 
between the dual-guides with which an efficient deletion can still occur has not yet been 
reported, therefore the frequency of the deletion was estimated for dual combinations ranging 
from 419bp to 63,428bp. To estimate the frequency with which the deletion occurs we 
quantified the amplification across both target sites compared to an untreated sample, as 
primer binding sites should be removed if the region between both guides has been excised 
(Figure 6a). We hypothesised that the larger the distance between the dual-guides the less 
frequent the deletion would be, while we found that for the lengths tested, ranging from 
419bp to 63,428bp, the greater the distance between the dual guides the less efficient the 
deletion was (Figure 6b), the decline in frequency was much more gradual than expected; the 
average of PCR 1 and PCR 2 for 419bp saw a 40% reduction in product, compared to 20% 




shown in supplementary table 6. While these results are encouraging for the use of a dual-cut 
to induce a therapeutically relevant deletion recent reports by Kosicki et al indicate that 
complex deletions and rearrangements may also be occurring, which may be contributing to 
the reduction in PCR product41. 
Allele-specific excision of coding region in TGFBI utilising an alternative dual cut 
approach 
In some cases, the target SNPs described (Supplementary Table 5) lie substantial distances 
apart, up to >18kb (Supplementary table 7); as the efficiency of deletion drops with 
increasing intervening distance, additional guides were designed that lie closer to a particular 
ASNIP guide yet still allow excision of exons (Supplementary table 8 and Supplementary 
figure 4). In contrast to the PAM discriminatory guides these were not allele-specific, they 
were selected to target the intronic region of both alleles (Figure 6c). It was hypothesised that 
the ASNIP guide will only cut the mutant allele while the common-intronic guide will cut 
both alleles; on the mutant allele when both cuts are made on that chromosome the region 
between these cuts may be deleted, while on the wild-type allele a cut should only occur with 
the common-intronic guide which, provided meticulous design has been applied to avoid 
important regulatory elements, at most, will result in a small indel and should have no 
functional effect (Supplementary Figure 5). The efficiency of the dual-cut was assessed in 
cells transfected with pairs of RNP complexes; dual combinations with a maximum 
difference of <3.5 kb, ranging in size from 602bp to 4008bp were tested (Supplementary 
Table 9), in line with previous results we found that small increments in distance had no 
significant effect on the efficiency of the deletion. On average the reduction of PCR 1 and 
PCR 2, and hence deletion, when compared to an untreated samples, was 38.87% ± 6.34% for 
PCR 1 (Figure 6d, shown in blue) and 33.64% ± 2.76% for PCR 2 (Figure 6e, shown in blue); 




fact that not all guide sequences perform at equal efficiencies, therefore one dual combination 
may cut more efficiently than the other.  
Improving the efficiency of deletion by the addition of a 50:50 ssODN 
Richardson et al demonstrated that the addition of a non-homologous single-stranded DNA 
template can increase gene disruption by altering repair outcomes 42. Therefore, we 
hypothesised that the introduction of a single-stranded oligonucleotide containing 50bp of the 
sequence flanking each cut site (50:50 ssODN) would encourage the DNA repair mechanisms 
to excise the region in between. When the ssODNs were co-transfected with the RNP 
complexes the average reduction of PCR 1 was 52.23% ± 3.77%, compared to transfection of 
only RNP complexes with which the reduction was 39.44% ± 5.21%, p<0.01 (Figure 6d, 
shown in orange); for PCR 2 the average reduction achieved with ssODN co-transfected with 
RNPs was 48.79% ± 3.43%, compared to transfection of only RNPs with which the reduction 
was 33.73% ± 3.43%, p<0.01 (Figure 6e, shown in orange). The significant increase in 
efficiency observed indicates it is possible to generate an efficient dual-cut within a cell, 
therefore a dual-cut approach could be used to achieve a therapeutic effect.  
Discussion 
Corneal dystrophies are a group of blinding disorders that affect the shape or transparency of 
the cornea, they are very attractive candidates for gene therapy due to the cornea’s small 
surface area, accessibility and immune privilege status43. The autosomal dominant inheritance 
observed with the majority of corneal dystrophies make them an unsuitable target for 
traditional gene replacement4,5, due to continued production of the mutant protein in the 
cornea; thus, a strategy that ablates the mutant protein is required. The critical role of TGFBI 
in wound repair is evident from the sudden emergence of corneal opacities in patients 




et al reported the upregulation of TGFBIp following injury to the rabbit cornea11 The key role 
of TGFBIp in wound repair was underlined by the effect that Tgfbi knockdown had upon tail-
fin regeneration in zebrafish, an established assay for monitoring wound repair; this is 
consistent with previous reports that Tgfbi is upregulated in a regenerating zebrafish tail fin44; 
transcriptome profiling of the tail-fin regeneration in zebrafish again revealed that tgfbi was 
differentially expressed during regeneration45, in addition Smad 1/5/8 proteins, involved in 
TGF-β signalling, were reported to be phosphorylated during fin regeneration therefore 
capable of initiating downstream signalling, further indicative of a critical role of the TGF-β 
signalling pathway and thus TGFBI in the wound healing process. These reports demonstrate 
that the role of TGFBI in wound repair is analogous in zebrafish, rabbit and human and thus 
suggests that a TGFBI corneal dystrophy gene therapy strategy that completely knocks out 
TGFBI in the cornea would not be a viable option as the resultant cornea would be incapable 
of repair following injury. As haplosufficiency of TGFBI has been demonstrated by the report 
of heterozygous nonsense mutations in TGFBI associated with a normal phenotype12,13, the 
development of a stringent allele-specific targeting strategy for the corneal dystrophies, that 
mitigates the effect of the mutant allele and leaves the wild-type allele intact, is a potential 
treatment strategy for these blinding dystrophies. Currently >60 TGFBI corneal dystrophy 
causing missense mutations have been described, we have previously reported more than one 
third of these mutations are not targetable by either a guide- or PAM specific approach19 
therefore a strategy based on individual targeting of each mutation would provide an 
incomplete approach to treat these dystrophies; it is well documented that wild-type 
S.pyogenes Cas9 can tolerate single base-pair mismatches within the seed region of the spacer 
19,46–48, conversely mutations within the PAM are much less tolerated and have been shown to 
impair the cleavage efficiency of Cas949–51, indicating that, in the case of wild-type 




Cas12a or variant nucleases with altered PAM specificities will broaden the potential of a 
guide-specific approach17,50,52–55, they will still require individual design for each mutation; 
due to this we have chosen to by-pass mutation-specific optimisation and develop a 
streamlined mutation independent approach utilising the well characterised wild-type 
S.pyogenes Cas9, however, the nucleases with altered PAM specificities may broaden the 
targeting capacity of ASNIP CRISPR and allow a dual-guide combination, highly specific for 
the mutant allele but close in proximity, to be designed.  
ASNIP CRISPR provides a promising alternative to mutation dependent approaches that can 
be used to treat any patient affected with an autosomal dominant monogenic disease 
irrespective of their causative mutation. Here we suggest a work-flow that will allow a 
completely personalised design for each patient to ensure both safe and effective guides are 
selected; for the gene of interest the SNPs matching the ASNIP criteria must first be 
determined, SNPs with a MAF of >0.1 that contain a PAM on one allele should be selected 
and subjected to haplotype analysis to ensure that the haplotypes present differ at enough 
positions in heterozygous combinations that a reasonable proportion of the population will be 
treatable by ASNIP CRISPR, this will provide a pool of guides based on commonly 
occurring SNPs that can be used to treat the majority of a given population. For each patient, 
phased sequencing of their genome should be undertaken, which will then indicate which 
guides in the pool of pre-designed guides are suitable for that patient.  These guides can be 
tested in a patient-derived cell line, such as a LCL, or primary fibroblasts to assess the 
genomic consequences of the selected guide in a personalised manner before treating the 
patient. In this new era of personalised medicine where progress will be made with great 
caution whole genome sequencing (WGS) will undoubtedly be a requisite for any patient 
undergoing gene editing therapies, in order to fully comprehend the success or failure of such 




mutation for autosomal disease but will also aid in the understanding of outcomes should 
unwanted off-targets effects or chromosomal translocations occur. Importantly, ASNIP 
CRISPR can be adopted for other autosomal dominant diseases for cases were phase cannot 
be pre-determined. This study acts as a proof of concept for ASNIP CRISPR to treat 
autosomal dominant disease. However, in order to induce a functional effect, further 
considerations for guide design must be applied. It is widely accepted that provided a 
premature stop codon resides ≥50-55 nucleotides upstream of the 3’ most exon-exon junction 
then the exon-junction complex will not be removed and thus nonsense mediated decay 
(NMD) will be induced56,57; thus, in order to induce NMD and selectively degrade the mutant 
allele guides that target early in the transcript will be most desirable, however depending on 
the phasing data this may not always be possible. When this concept is applied to TGFBI a 
premature termination codon no later than 50-55 nucleotides in exon 15 will result in NMD; 
this is evident from phenotype associated mutations in TGFBI. All mutations associated with 
TGFBI corneal dystrophies are missense mutations or in frame indels with the exception of a 
frameshifting single base deletion at codon 626 reported by Munier et al 58, the result of this 
frameshift mutation is the addition of 43 missense amino acids and premature termination at 
codon 669, which is less than the required 50-55nt distance from the 3’ most exon-exon 
junction, therefore NMD is predicted not to occur and the nonsense transcript is translated. In 
addition, if common intronic guides are required, such as those described here to increase 
deletion efficiency, care must be taken to ensure any indels they may induce do not disrupt 
any regulatory elements. In a similar approach used to target the Huntington gene (HTT), 
common intronic guides were found to affect expression of the normal allele due to the 
targeting of intronic transcription factor binding sites59, however in contrast to our approach 
these guides were designed to target intron 1 where they are more likely to affect regulation 




an intronic region will have no functional effect. However, Kosicki et al recently reported 
single guides targeted to intronic regions produced deletions of up to 2kb at significant 
frequencies; they demonstrate that transfection of 10 different guides singly, located 263–520 
bp from the nearest exon, caused a 8–20% reduction in their gene of interest, while 2 guides 
> 2 kb away caused a 5–7% loss of their gene of interest41. While this would indicate that, 
provided they are highly allele-specific, single ASNIP guides could have a functional effect 
by inducing larger deletions, it raises concerns about the types of alterations that Cas9 
generates and whether or not current detection methods are capturing a complete picture of 
the changes induced.  
This study focusses on the issue of on-target allele-specificity in relation to the TGFBI 
corneal dystrophies; however, for translation to the clinic a number of key hurdles will have 
to be overcome, including genome wide specificity and efficiency of delivery to the correct 
cells in the cornea. Furthermore, potent targeting of the correct cell population must be 
achieved; the majority of TGFBIp is produced in the corneal epithelium, the epithelium is 
continually turned over and repopulated via the limbal epithelial stem cells (LESCs), thus, in 
order to permanently correct the TGFBI corneal dystrophies efficient delivery to the LESCs 
must be achieved. The continued development of engineered nucleases with improved 
specificity will further enhance the ASNIP CRISPR approach 55,60–62. In order to minimise 
off-target cleavage, non-viral delivery systems that allow delivery of Cas9 mRNA or Cas9 
protein, that would not persist in the cell for a long time, would be most desirable. Current 
efforts to develop a non-viral system to deliver these components have been promising and it 
is likely they will bring about the next frontier in genome editing63–66. The era of personalised 
genome editing has progressed with unprecedented pace, other hurdles such as efficiency and 
delivery remain to be addressed, however ASNIP CRISPR offers a promising strategy to 
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Figure 1: Effect of Tgfbi knockdown on zebrafish tail-fin regeneration a) At day 0 the tail fin 
was amputated perpendicular to the anterior/posterior plane of the fish, 3 dpa tgfbi morpholino 
mixed with rhodmaine red was injected distal to each bone array on the dorsal side of the fin. 
5 dpa regenerated fins were imaged and regeneration of fins deficient in Tgfbi were compared 
to untreated fins b) The area of the treated and untreated fins were calculated and normalised 
to the width of the fin, regeneration in the Tgfbi deficient fin was significantly impaired in 
comparison to the untreated fin (p=****), indicating TGFBI has a critical role in wound repair 
c) LC-MS/MS was used to confirm a reduction of Tgfbi in the regenerating fins, Tgfbi was 











Figure 2: Linkage disequilibrium (LD) of the identified ASNIP SNPs in the coding region of 
the TGFBI gene – plots were generated using the 1000 Genomes Project phase 3 data for East 
Asian (EAS), Han Chinese in Beijing (CHB) and Japanese in Tokyo (JPT) populations, black 
indicates very strong LD, while a white indicates no LD a) LD plot showing the association 
between the 24 SNPs containing a PAM on only allele identified across the TGFBI locus for 
the EAS population; 3 LD blocks were found, the first block (EAS-B1) spans 1kb within intron 
1-2 (rs2237063- rs756462), the second block (EAS-B2) spans 21kb from intron 2-3 
(rs11738979) to intron 13-14 (rs10064478) and finally the third block (EAS-B3) spans 1kb 
from intron 14-15 (rs6880837) to intron 15-16 (rs6865463) b) LD plot showing the association 
between the 24 SNPs containing a PAM on only allele identified across the TGFBI locus for 
the CHB population; 3 LD blocks were identified, ; the first block (CHB-B1) spans 1kb within 
intron 1-2 (rs2237063- rs756462), the second block (CHB-B2) spans 21kb from intron 2-3 
(rs11738979) to intron 13-14 (rs10064478) and finally the third block (CHB-B3) spans 1kb 




between the 24 SNPs containing a PAM on only allele identified across the TGFBI locus for 
the JPT population, 2 LD blocks were found in the 1000 Genomes JPT population; the first 
block spans 25kb from intron 1-2 (rs2237063) to intron 10-11 (rs6860369) and the second 
block spans 2kb from intron 13-14 (rs6880837) to intron 15-16 (rs6865463) d,e,f) Haplotype 
frequencies of the identified ASNIP SNPs in the TGFBI gene in the d) EAS e) CHB and f) JPT 
populations. The blue indicates the major allele and red indicates the minor allele, numbers 
next to each haplotype bar are haplotype frequencies, in the crossing areas a value of 



















Figure 3: Haplotype analysis of R124H Japanese patient a) Phased sequencing, of a Japanese 
corneal dystrophy patient harbouring a R124H mutation, revealed the patients haplotype 
blocks; comparison to our haplotype analysis of the TGFBI locus in the Japanese population 
revealed the patient had JPT-B1H1 which co-segregated with JPT-B2H1 and JPT-B1H2 which 
co-segregated with JPT-B2H2, the patient differed at one position (rs11738979) in JPT-B1H1 
as the patient was homozygous for the major allele. Blue indicates the major allele and red 
indicates the minor allele. b) The determination of the R124H patients haploblocks by phased 
sequencing allowed the identification of SNPs that contain a PAM on only the allele associated 
with the R124H mutation. Yellow shading and ticks indicate a combination of haplotypes that 
generate a heterozygote at this position, offering only one PAM-generating allele, therefore 
providing a potential SNP for ASNIP CRISPR, grey indicates that either there is no PAM-
associated allele present on either haplotype or each haplotype has the same PAM-associated 






Figure 4: In vitro assessment of ASNIP guides allele-specificity a) Based on the phased 
sequencing data 12 ASNIP guides were designed that i) are associated with a PAM only on 
one allele ii) lie in cis with the R124H mutation and iii) have good scores using the in silico 
tools. Coding exons in TGFBI are shown by the green boxes, length in base pairs of each exon 
and intronic regions are indicated across the region. Location of the 12 ASNIP guides and the 
R124H mutation are depicted by black drop-down arrows b) Initially in vitro digests were used 
to determine the allele-specificity of the 12 ASNIP guides. RNP complexes were incubated 
with templates containing ‘No-PAM allele’ or ‘PAM-associated allele’ sequences for the 
respective SNPs, for each digest lane 1 = ‘No PAM’ digested, lane 2 = ‘PAM-associated’ 
digested, lane 3 = ‘No PAM’ undigested, lane 4 = ‘PAM associated’ undigested. Undigested 
bands in the treated samples were normalised to undigested samples and were quantified to 
determine cleavage efficiency. SNPs that have a non-canonical PAM (NAG/NGA) on the wild-






Figure 5: Allele-specificity of ASNIP guides tested in a patient-derived cell line a) LCLs were 
transfected with RNPs for each of the 12 ASNIP guides. Targeted resequencing across the on-
target cut site was used to determine the allele-specificity of each guide. Orange indicates % of 
indels that occurred on the ‘PAM-associated’ allele and blue indicated % of indels that occurred 
on the ‘No PAM’ allele. On average 96.3% of indels were observed on the ‘PAM associated’ 
allele with only 3.7% of indels occurring on the ‘No PAM’ allele. b) The most frequent indels 
detected for each ASNIP guide, the SNP is shown in bold, the PAM is underlined and the indel 












Figure 6: Allele-specific dual-guide approach targeted to TGFBI a) Schematic to show 
quantification of dual-cut – dual-guides are shown by the black arrows, PCR amplification 
across target site 1 is denoted as PCR 1 and shown by the red arrows, PCR amplification across 
target site 2 is denoted as PCR 2 and shown by the green arrows. If both guides cut in the same 
cell and intervening region is excised then the binding sites for PCR 1 REV and PCR 2 FWD 




reduced if a frequent productive edit has occurred b) Fold change for the average of PCR 1 and 
PCR 2 compared to untreated is shown for dual combinations ranging in size from 419bp to 
63,428bp. The efficiency of the deletion reduces as the distance between the guides increases, 
indicating the closer the dual-guides are the more frequent the productive edit is c) Schematic 
showing the predicted cleavage of each guide utilised. As the ASNIP guides are substantial 
distances apart common-intronic guides are designed to overcome this limitation, the common-
intronic guides are shown in bold and are predicted to cleave both alleles, while the ASNIP 
guides should only cleave the mutant allele d,e) The addition of a ssODN containing 50bp of 
each flanking region in the dual-guide combination was shown to increase the frequency of a 
productive edit. The fold change of PCR 1 (d) and PCR 2 (e) in cells transfected with RNP 
only is shown in blue and of fold change of PCR 1 and PCR 2 in cells transfected with RNP + 
ssODN is shown in orange. The addition of a 50:50 ssODN appears to increase the frequency 



















Supplementary Figure 1: Mutation hotspots across TGFBI – The TGFBI gene, including 
untranslated regions (UTRs) (shown by light blue shading) and introns (shown by black 
interlinking lines), covers ~35kb, and there are 17 coding exons (shown by dark blue shading). 
To-date 62 missense mutations within TGFBI have been associated with corneal dystrophies, 
each mutation is depicted by a single drop-down line and the colours correspond to the 
dystrophy the mutation is associated with, described in the colour coded key. These missense 
mutations are found in exons 4 to 16 of the gene; however, the majority of mutations are 











Supplementary Figure 2: ASNIP design based on the TGFBI locus a) Mutational workflow 
for ASNIP CRISPR. Non-disease causing mutations within the TGFBI locus with a minor 
allele frequency (MAF) of >0.1 are identified, these SNPs are then analysed to determine if 
they generate a novel S.pyogenes PAM (NGG), guides are designed and prospective guides are 
ran through in silico design programs to determine the most promising pool of guides. b) 
Genomic location of the TGFBI locus. There are no flanking genes within a >70kb region either 
up or downstream of TGFBI, indicating gene editing events are not likely to disrupt 


















Supplementary Figure 3: Haplotype analysis to determine proportion of population 
targetable by ASNIP CRISPR a,b,c): SNPs across each haplotype in the a) EAS population 
b) CHB population and c) JPT population were assessed to determine which have the PAM 
generating allele and which are not targetable. Blue indicates the major allele and red indicates 
the minor allele, green indicates a PAM-generating allele is present while orange indicates it is 
not targetable at this position d,e,f) All possible heterozygous haplotype combinations for the 
d) EAS population e) CHB population and f) JPT population were assessed using only the large 
haploblock (EAS-B2, CHB-B2 and JPT-B1) to determine the total % of each haplotype that 
has targetable SNPs. Yellow shading and ticks indicate a combination of haplotypes that 
generate a heterozygote at this position, offering only one PAM-generating allele, therefore 
providing a potential SNP for ASNIP CRISPR, grey indicates that either there is no PAM-
associated allele present on either haplotype or each haplotype has the same PAM-associated 







Supplementary Figure 4: Schematic to shown the different dual combinations used and their 
location relative to the exon/intron regions in TGFBI. Exons are shown in red, introns are 
shown in blue, each guide is shown vertically along the top of the figure, each dual combination 
is shown by a yellow box spanning the region between the two guides, the drop-down numbers 






Supplementary Figure 5: The greater the distance between the dual-guides the less frequent 
the productive edit will be, the distance between the original ASNIP guides is substantial 
therefore to overcome this limitation common-intronic guides were designed. The ‘No PAM’ 
allele is shown in blue and the ‘PAM associated’ allele is shown in orange. The ASNIP guide 
(shown in red) is predicted to only cut the ‘PAM associated’ allele while the common-intronic 
guide (shown in green) should cut both alleles; on the ‘PAM associated’ allele when both cuts 
are made in a cell the region between these cuts may be excised resulting in a productive edit 
(shown in purple), while on the ‘No PAM’ allele a cut should only occur with the common-









Supplementary table 1: Scheduled inclusion list for PRM method 
Protein Peptide sequence Mass (m/z) CS* (z) Start (min) End (min) 
TGFBIp TQGPNVCAMQK 617,2894 2 10,4 20,4 
TGFBIp ICGKPTVISYECCPGYEK 720,9969 3 17,5 27,5 
TGFBIp GCPAALPLVNIYK  708,3894 2 31,4 41,4 
TGFBIp VITAITNDVNSIIDTDDDLDTLR  844,7607 3 40,4 50,4 
TGFBIp TLLELAEGSVVTTAAK 534,9698 3 33,6 43,6 
TGFBIp DAGLNDHLVGSESVTLLAPLNEAFKDK 714,1212 4 38,1 48,1 
TGFBIp SLYHGQELETLGGLK a 548,9579 3 23,8 33,8 
TGFBIp YANMFLVDSILTPPQGTVMDVLK 851,4428 3 48,2 58,2 
TGFBIp FSTLVGAIQK 532,3109 2 22,3 32,3 
B-actin VAPEEHPVLLTEAPLNPK 652,0263 3 23,8 33,8 
B-actin LCYVALDFEQEMGTAASSSSLEK 846,0576 3 38 48 
B-actin DLYANTVLSGGTTMYPGIADR 739,0282 3 34,5 44,5 
 
  
*CS: Charge state, 
a 




Supplementary Table 2: List of oligo nucleotides used 
Oligo Name Oligo Sequence (5' - 3') 
Cleavage template FWD ACCCCAACATCTTCGACGCGGGC 
Cleavage template REV TGCTGTCCTGCCCCACCCCA 
rs72794904 956bp FWD GGCAGTGTATTTCTTTCAGAGGA 
rs72794904 956bp REV GAGCCGAGATCATGCCACT 
rs72794904 238bp FWD CCAAGTGCCAGTCAATCCTG 
rs72794904 238bp REV TGCAAGAGAGGACATCAATTTGA 
rs2282790 748bp FWD GGCCTCAGAGCAGGTATCAC 
rs2282790 748bp REV TAGGTCCCTTAGGCCTCCTG 
rs2282790 240bp FWD TGGGCTACGGATCTTCCCAA 
rs2282790 240bp REV CATCTCTGCAACAGTACCTGC 
rs1989972 708bp FWD GTTCAGCTCCCTTGCGGTAT 
rs1989972 708bp REV CAGGCTATTGTCTTGGGACTCA 
rs1989972 249bp FWD GCCCTGACATGAGGACTTTGA 
rs1989972 249bp REV CCAGCTAAATCCAGGGAGAGC 
rs6860369 762bp FWD GGGGCCTCTCTAACCGTTCT 
rs6860369 762bp REV GCCGGGCAAGAAAACAAACT 
rs6860369 215bp FWD TCCCAGCCTTAATAACCCATCC 
rs6860369 215bp REV GGTCCATCGTGAACAGGGTC 
rs6894815 797bp FWD ATAGATTTGCCCTGGGTGGG 
rs6894815 797bp REV AAGAAAAACAGAGTAGTGGTTGAAA 
rs6894815 241bp FWD GGCCTGAGATAGATTTGCCC 
rs6894815 241bp REV CTCAGTCCTCACAGCAGTGTAT 
rs10064478 961bp FWD TCCCCAGTCTAACACAGGAC 
rs10064478 961bp REV GAGGCAGGACTGAGGTTCAA 
rs10064478 150bp FWD AAAATTAGCTGGGCGTGGTG 
rs10064478 150bp REV TGGAGTTTCAATCTTGTCGCC 
rs11956252 741bp FWD AGCCAGGAGAGAAAGTCATGG 
rs11956252 741bp REV TCCCCCAACTAAAACCCTCC 
rs11956252 210bp FWD CACCCACTTGTGGTTGGGGA 
rs11956252 210bp REV CCCCACCCTCTTCATTCTTCAG 
rs7725702 702bp FWD GGCTCCTTCAGTCAACAAGGT 
rs7725702 702bp REV TCCCTCACCCTCCGATTCTG 
rs7725702 247bp FWD TCTTCTCAGGAAAGCAGGGTG 
rs7725702 247bp REV CTCCCCAGAAGGGTTAGAGG 
rs4976470 829bp FWD ATGTAGCCTCAAATCCCAGCC 
rs4976470 829bp REV GCACACCTGACTATGGCTCT 
rs4976470 168bp FWD GCAACAGATCAAGTGACACCT 
rs4976470 168bp REV GGGGCTTGATATGGTTTGGC 
R124H 988bp FWD TGAGTTCACGTAGACAGGCA 
R124H 988bp REV ACAGCTTAAACCCCAGAAACCA 




R124H 187bp REV GTTCCCCATAAGAGTCCCCC 
CI-1 703bp FWD CCAGTTGGTTGGCTGTAGGT 
CI-1 703bp REV ATCCCATCGGCTCTCTAGCA 
CI-1 73bp FWD TCCAGCAGGTGAATGAATCC 
CI-1 73bp REV TACTCCTCTCTCCCACCATTCC 
CI-2 925bp FWD CTGGAAAGGTCCCTGGCTTT 
CI-2 925bp REV GGCTCACAGAGCAAGTGTCA 
CI-2 117bp FWD TGCTTTGTGTCCTCTGACCAT 
CI-2 117bp REV AGTGGTCACCCCTGAAATGAA 
CI-3 736bp FWD GTTGCCGAGCCTGACATCAT 
CI-3 736bp REV CGCAAACCTAGCAGGCATCT 
CI-3 173bp FWD GACACATTGCTCTTTGCGGA 
CI-3 173bp REV GAGAGGCAGGACTGAGGTTC 
CI-4 818bp FWD TCAGAACAGCAGGGTGACTTG 
CI-4 818bp REV CCAGCTGTGCAAGGGCTTTA 
CI-4 253bp FWD AGAAAACCAGAACATCGGGC 




















































Supplementary Table 3: Table showing the ASNIP CRISPR mutational analysis for the 
TGFBI locus. Initially SNPs in the 50kb flanking regions and across the TGFBI coding 
region were filtered to leave only those with a MAF of >0.1. Each SNP and flanking 
sequence was then individually assessed to determine if it generates a novel S.pyogenes Cas9 
PAM. Those that did generate a PAM were then further investigated to determine if a non-
canonical PAM exists on the alternative allele. These SNPs (both with and without non-
canonical PAMs on the alternative allele) were then cross-checked to the phased sequencing 
data from the R124H Avellino corneal dystrophy patient to determine if the PAM generating 
SNP lies in cis with the R124H mutation. Guides were then designed for those that are 
associated with a PAM on the same chromosome as the mutation. Guide sequences were then 
inputed into the in silico MIT CRISPR and Benchling design tools and sgRNAs were 

































Supplementary Table 4: Haplotype analysis of the TGFBI locus following phased sequencing of the 







Supplementary table 5: Guide sequences of 12 ASNIP guides - designed based on the phased 
sequencing results of the R124H Japanese Avellino corneal dystrophy patient  
 
 












Supplementary table 8: Common-intron guide sequences 
 
 







rs72794904 & rs2282790 18691 Both in 5' UTR
rs2282790 & rs1989972 14,131
rs1989972 & rs6860369 13524
s6860369 & rs6894815 4582
rs6894815 & rs10064478 419
rs10064478 & rs11956252 6560
rs11956252 & rs7725702 3607 Both in 3' UTR















5 Paper IV- Delivery of CRISPR/Cas9 by a dual-AAV system to treat 
FECD  
Kathleen A. Christie, Eleonora Maurizi, Caroline Conway, Marie Lukkassen, Paul S. Cassidy, 
Shyamasree De Majumdar, Kevin Blighe, Davide Schiroli, Laura C. Mairs, Hildegard Büning, 
Pete Humphries, Colin Willoughby, M. Andrew Nesbit, C.B.Tara Moore 
 
5.1 Aims and author contributions 
The main aims of this paper were to: 
1. Identify an AAV vector that could efficiently transduce the corneal endothelium in vivo 
via an intracameral injection 
2. Design an allele-specific sgRNA using the Col8a2 mutation, causative of Fuchs’ 
endothelial corneal dystrophy 
3. Determine the allele-specificity of this guide in vitro 
4. Package this guide into a dual-AAV vector system and deliver packaged vectors via an 
intracameral injection 
5. Determine if indels occurred in the cornea in vivo 
 
Contributions 
I carried out all HCE-S and B4G12 transductions and prepared all samples for FACS analysis. 
I performed all intracameral injections in mice for both AAV-GFP and AAV-Cas9 & AAV-
sgRNA. I performed all imaging using the in vivo IVIS imager. I wrote the manuscript and 
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Abstract 
Gene therapy offers a promising treatment strategy for the corneal dystrophies, however the 
inability to achieve efficient and potent delivery to the corneal layers poses a substantial hurdle 
for the translation of these therapies to the clinic. We compared 3 AAV serotypes for their 
ability to transduce human corneal epithelial and endothelial cells in vitro. Furthermore, we 
tested the ability of these 3 serotypes to transduce the corneal layers in vivo following an 
intracameral injection. We demonstrate AAV-2/9 has the ability to successfully transduce all 
corneal layers following an intracameral injection, identifying a vector capable of delivering 
gene therapy reagents to all corneal layers. Finally, we package S.pyogenes CRISPR/Cas9 into 
AAV-2/9 in a dual-vector system and demonstrate it is possible to achieve 25.7% editing 
efficiency in the whole cornea. These findings indicate both efficient delivery and editing by 







The cornea is an avascular, transparent tissue found in the anterior segment of the eye. There 
are a number of corneal dystrophies that all act to alter the shape or transparency of the cornea1. 
Fuchs’ endothelial corneal dystrophy (FECD) is a common, age-related, inherited degenerative 
disease of the corneal endothelium which in advanced disease affects all layers of the cornea. 
It is identified by the presence of corneal guttae, which are excrescences of Descemet’s 
membrane. These corneal guttae are associated with a progressive loss of corneal endothelial 
cells, the loss in endothelial cells below a critical threshold results in the inability of the corneal 
endothelium to successfully dehydrate the stroma; causing fluid accumulation in the stroma 
and the development of painful epithelial bullae leading to corneal clouding and a reduction in 
visual acuity.2 In the US, approximately 5% of Caucasians over 40 years of age exhibit corneal 
guttae which may develop to corneal decompensation.3 There are two categories of FECD; 
early-onset which presents with symptoms in the first decade and late-onset which presents 
with symptoms in the sixth decade.4 Within these two categories there are 8 subtypes, in all 
subtypes of FECD the genetic locus has been identified, however the causative gene has not 
been elucidated in all cases.5 (Table 1)  
Due to the monogenic, penetrant genetics of these dystrophies they are an ideal target for gene 
editing solutions. A requisite for efficient gene editing is the selection of a robust delivery 
vehicle. Adeno associated virus (AAV) has been the most widely used vector in ocular gene 
replacement therapy thus far; the success of AAV in gene augmentation is largely due to its 
lack of immune response and persistence in the nucleus,  AAV-2 has been extensively used in 
clinical trials for the treatment of Leber’s congenital amaurosis6. A multitude of AAV vectors 
of various serotypes have been shown to successfully transduce all layers of the cornea. Of a 
study testing AAV-2/1, AAV-2/2, AAV-2/5 and AAV-2/8 on both human corneas ex vivo and 




were delivered via an intrastromal injection and AAV-2/8 was found to achieve long-term 
transgene expression in the stroma keratocytes. AAV-2/9 and AAV-2/8 have shown successful 
transduction of the superficial cells of the stromal layer after epithelial debridement, with 
limited transduction of the same cells by AAV-2/6. 8 Following an intrastromal injection in 
human corneas ex vivo an AAV-8 and AAV-9 chimeric capsid vector (AAV8G9) was shown 
to successfully transduce the stromal layers in addition to some endothelial cells.9 AAV-2/9 
has been shown to successfully transduce the cornea endothelium in mouse in vivo, via an 
intracameral injection.10 A novel synthetic AAV, Anc80L65, was shown to efficiently 
transduce the corneal stroma and endothelial cells. 11   
CRISPR/Cas9 has proven to be a robust tool for mammalian gene editing and indeed ocular 
gene editing in the retina12. CRISPR/Cas9 gene editing requires a i) Cas9 nuclease ii) single 
guide RNA (sgRNA) and iii) protospacer adjacent motif (PAM), which for S.pyogenes Cas9 is 
5’ – NGG – 3’. Cas9 will search the genome for the NGG PAM, it will then determine if the 
sgRNA binds specifically to the adjacent sequence. If the sequences are sufficiently 
complementary the Cas9 will bind and generate a double strand break (DSB), different gene 
editing outcomes can be achieved due to the repair processes of the DSB. Early onset FECD is 
caused by dominant negative missense mutations in Col8a2. Due to the dominant negative 
nature of these mutations ablation of only the mutant allele would potentially be a viable 
treatment strategy.  
Here we demonstrate successful transduction of all corneal layers by an intracameral injection 
of AAV-2/9, in addition we demonstrate gene editing of a Col8a2 mutation causative of early-
onset FECD. This is the first study to our knowledge of efficient gene editing of the corneal 
endothelium and acts as a proof of concept study for gene editing in the corneal endothelium.   
Results 




There have been a plethora of studies using AAV to target the anterior segment of the eye but 
there is little uniformity in both the vectors used, the mode of delivery and whether the study 
was carried out in vitro, ex vivo or in vivo. Thus we have tested 3 different single-stranded 
AAV serotypes in our delivery systems to determine the most efficient vector for the corneal 
layers. AAV-2 is the most characterised AAV serotype so we decided to test AAV-2 in addition 
to 2 AAV hybrids containing the AAV-2 genome and AAV-5 and AAV-9 caspids. The 3 
vectors tested in this manuscript will be denoted as AAV-2/2, AAV-2/5 and AAV-2/9. Initially 
the 3 AAV-GFP vectors were transduced with two different multiplicities of infection (MOI 1 
000 and MOI 10 000) into human corneal epithelial cells (HCE-S) and human corneal 
endothelial cells (B4G12), 48 hours after transduction the % of GFP+ cells were determined as 
a measure of transduction efficiency. For HCE-S AAV-2/2 achieved 41.65% transduction at a 
MOI of 10,000 compared to 9.25% and 0.1% with AAV-2/5 and AAV-2/9 respectively (Figure 
1a). While for B4G12s AAV-2/5 achieved 63.28% transduction at a MOI of 10,000 compared 
to 32.73% and 21.8% with AAV-2/2 and AAV-2/9 respectively (Figure 1b). 
Assessment of transduction efficiency of AAV-GFP serotypes in vivo 
However, several studies have reported that in vitro and in vivo tropisms can vary 
substantially13–15; thus we decided to proceed to in vivo with all aforementioned vectors. AAV 
serotypes expressing GFP were injected by intracameral injection; in vivo imaging confirmed 
successful transduction of the anterior segment by all 3 vectors at day 4 (Figure 2 a-c), at day 
7 fluorescence was not detectable by AAV-2/5(Figure 2d), suggesting that the cornea itself was 
not transduced and that the original signal came from the aqueous drainage through the 
trabecular meshwork into Schlemm’s canal. The IVIS is able to detect a fluorescence signal 
from the anterior surface but it is necessary to confirm from which corneal layer the signal 




microscopy confirmed AAV-2/9 to successfully transduced all corneal layers (Figure 2 g) and 
this vector was chosen for the packaging of gene-editing reagents. 
Mutational analysis of L450W mutation and evaluation of allele-discrimination in vitro 
Mutational analysis of L450W, a dominant negative missense mutation in Col8a2, revealed 
that the TTG>TGG change resulted in a novel PAM for S.pyogenes Cas9 (Figure 3a), it has 
previously been reported allele-specific editing can be achieved by designing a sgRNA utilising 
a novel PAM16–18. Thus a sgRNA utilising the PAM created by L450W was designed 
(sgL450W) and the ability of sgL450W to distinguish between wild-type and mutant alleles of 
Col8a2 was determined via an in vitro digestion. sgL450W appeared to selectively cleave the 
mutant Col8a2 allele in vitro and was chosen to be packaged into AAV-2/9 (Figure 3b). 
Allele specific editing of L450W mutation in vivo 
All of the necessary components for CRISPR/Cas9 gene editing exceed the packaging capacity 
of AAV (<5 kb), therefore a dual-AAV CRISPR/Cas9 system was employed in which 
S.pyogenes Cas9 and sgL450W were packaged separately (Figure 4a). The dual-AAV system 
was co-injected into L450W knock-in mice by intracameral injection and indels were detected 
via TIDE analysis19, which revealed 25.7% of indels in the whole cornea (Figure 4b). 
Discussion 
The corneal epithelium is known to be a rapidly dividing tissue, with complete turnover of the 
murine corneal epithelium taking around 3 weeks20 while in the human it is reported to take 1-
2 weeks21, however the corneal endothelium consists of non-dividing cells22. In the case of the 
corneal epithelium successful gene disruption by NHEJ would require gene editing to occur in 
the limbal epithelial stem cells (LESC) as it will be these cells that repopulate the tissue, LESCs 
are located deep in the palisades of Vogt therefore efficient targeting of these cells may prove 




occurs within a cell the mutant protein will no longer be produced for the lifetime of that cell 
as such the corneal endothelium is a promising tissue to target for gene disruption via NHEJ.  
Here we target Col8a2 as a proof of concept for gene editing in the corneal endothelium; 
mutations in COL8A2 cause early-onset Fuchs corneal dystrophy and exhibit mendelian 
inheritance and complete penetrance, therefore would appear to be a good candidate for gene 
therapy. However, as COL8A2 only has 2 exons and the disease causing mutations occur in the 
last exon, restrictions of nonsense mediated decay (NMD) quality checks would limit gene 
disruption via NHEJ as a targeting strategy for this gene24,25. Such that, NMD will only occur 
if the premature stop codon resides ≥50-55 nucleotides upstream of the 3’ most exon-exon 
junction, as the COL8A2 mutation is located in the last exon NMD would not occur thus a 
truncated protein will be produced that could potentially exacerbate the phenotype. Thus, this 
study acts as a proof-of-concept for viral gene editing in the corneal endothelium that can be 
applied to more suitable causative mutations. A trinucleotide repeat expansion (TNR) in 
transcription factor 4 (TCF4) is the most prevalent cause of FECD, 70% of FECD cases are 
due to this TCF4 TNR. Delivery of a dual-guide approach to remove this expansion would 
offer a promising avenue for treatment. 
A pressing concern of viral delivery of gene-editing reagents is the long-term expression of the 
transgene. The persistent expression of Cas9 may increase the risk of off-target cleavage at 
genomic sites other than the intended target. One possible strategy to overcome this limitation 
would be to drive expression of the transgene by an inducible promoter. O’Callaghan et al 
demonstrated it was possible to transduce the corneal endothelium with AAV-2/9 expressing 
MMP-3 under control of a doxycycline-inducible promoter and induce expression by topical 
application of doxycycline10. In addition, in a dual-AAV system it is possible to package Cas9 




for both the intended target and the Cas9 protein itself26,27. Both Cas9-sgRNA complexes will 
be produced, allowing on-target cleavage to be achieved in addition to the inactivation of Cas9 
thus limiting its expression. 
Due to the cornea’s natural function as a structural barrier to the entry of foreign bodies into 
the eye, delivery to the cornea poses a substantial challenge. Delivery of gene editing reagents 
via AAV offers a promising approach to overcome this hurdle and facilitate gene editing 
strategies for the corneal dystrophies. 
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Methods 
Cell culture and transduction of AAV serotypes 
B4G12 cells represent a model of differentiated human corneal endothelial cells28, culture 
flasks were coated with 10 µg/ml laminin (Sigma) and 10 mg/ml chondroitin sulfate (Sigma), 
cells were cultured in Human Endothelial-SFM supplemented with 10 ng/ml human 
recombinant bFGF (Thermo). HCE-S, a spontaneously immortalised human corneal epithelial 
cell line (a gift from J.T.   Daniels, Institute of Ophthalmology, University College London, 
UK)29 were grown in DMEM medium (GlutaMAX; Invitrogen, UK) supplemented with 10% 
Fetal Bovine Serum (FBS)(Thermo Fisher, UK). Cells were incubated at 37° C with 5% CO2 
and passaged following standard laboratory procedures. For viral vector transduction, cells 
were infected with AAV serotypes at a multiplicity of injection of 1,000 or 10,000 viral 
genomes/cell. Cells were harvested 48 hours after transduction and transduction efficiency was 





Intracameral injection of AAV serotypes 
To assess delivery of AAV to the cornea injections were performed on wild-type C57BL/6 
mice, to assess allele-specific gene editing injections were performed on L450W Col8a2 
knock-in mice previously reported30. Animals were anaesthetised by intra-peritoneal injection 
of ketamine and xylazine. Pupils were dilated using one drop of tropicamide and phenylephrine 
on each eye. 1.5 μl of virus at a stock titre of 1x1013 vector genomes per ml was initially back-
filled into a glass needle (ID1.0 mm, WPI) attached to a Hamilton 10uL Syringe (ESSLAB). 
An additional 1 μl of air was then withdrawn into the needle. Animals were injected 
intracamerally just above the limbus. The air bubble prevented the reflux of virus/aqueous back 
through the injection site when the needle was removed. Fucidic gel was applied topically 
following injection as an antibiotic agent.  
IVIS in vivo imaging of fluorescence 
To assess delivery of AAV to the cornea, experiments measuring fluorescence were performed 
on wild-type C57BL/6 mice, all mice used for live imaging were aged between 12 and 25 
weeks old. For imaging, mice were anaesthetised using 1.5–2% isoflurane (Abbott 
Laboratories Ltd., Berkshire, UK) in ~1.5 l/min flow of oxygen. A Xenogen IVIS Lumina 
(Perkin Elmer, Cambridge, UK) was used to quantify fluorescence.  
Fluorescent microscopy 
Eyes were enucleated 7 days post-injection of AAV, was washed in PBS and fixed in 4% 
paraformaldehyde overnight at 4 °C. Fixed eyes were frozen in PolyFreeze (Sigma) in an 
isopropanol bath immersed in liquid nitrogen and cryosectioned (CM 1900, Leica 






In vitro digestion to determine on-target specificity 
A double-stranded DNA template was prepared by amplifying a region of the luciferase 
reporter plasmid containing either wild-type or mutant Col8a2 sequence using the primers 
listed in Supplementary Table 1. A cleavage reaction was set up by incubating 30nM 
S.pyogenes Cas9 nuclease (NEB UK) with 30nM synthetic sgRNA (Synthego) for 10 minutes 
at 25˚C. The Cas9:sgRNA complex was then incubated with 3nM of DNA template at 37˚C 
for 1 hour. Fragment analysis was then carried out on a 1% agarose gel. 
Sanger sequencing across target locus 
7 days post injection gDNA was extracted from the whole cornea (QIAamp DNA Mini Kit, 
Qiagen) and PCR amplified using primer pairs listed in Supplementary Table 1. PCR products 
were purified using the Wizard® PCR Preps DNA Purification System (Promega). PCR 
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Table 1: Subtypes of Fuchs’ endothelial corneal dystrophy and causative genes 
Corneal Dystrophy Genetic Locus Genetic Known Causative Gene 
FECD 
Early Onset 1q34.3-p32 (FECD 1)  Yes  COL8A2 
Late Onset 
13pter-q12.3 (FECD 2) 
Some cases 
Unknown 
18q21.2-q21.3 (FECD3) TCF4 
20p13-q12 (FECD 4) SLC4A11 
5q33.1-q35.2 (FECD 5) Unknown 
10p11.2 (FECD 6) ZEB1 
9p24.1-p22.1 (FECD 7) Unknown 




























Figure 1: a) Assessment of transduction efficiency of AAV-GFP serotypes in Human Corneal 
Epithelial cells (HCES) – HCES were transduced with AAV serotypes (AAV 2/2, AAV 2/5, AAV 
2/9) carrying GFP as the transgene at GOI 1000 and GOI 10000. 48 hours after transduction %GFP+ 
cells were measured using flow cytometry, n=3. AAV 2/5 appeared to transduce HCES with the 
highest efficiency. b) Assessment of transduction efficiency of AAV-GFP serotypes in Human 
Corneal Endothelial cells (B4G12s) – B4G12s were transduced with AAV serotypes (AAV 2/2, 
AAV 2/5, AAV 2/9) carrying GFP as the transgene at GOI 1000 and GOI 10000. 48 hours after 
transduction %GFP+ cells were measured using flow cytometry, n=3. AAV 2/5 appeared to 
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Figure 2: a-f) In vivo imaging of 3 AAV-GFP serotypes delivered via intracameral 
injection into the mouse eye – AAV serotypes (AAV 2/2, AAV 2/5, AAV 2/9) containing 
GFP as the transgene were all delivered via an intracameral injection into the left eye and 
the right remained untreated as a control. Using an IVIS in vivo imager the presence of 
GFP was detected in real-time 4 and 7 days post injection. The red and yellow colour 
represents the intensity of the fluorescence and not the colour of the fluorescent signal. At 
day 7 AAV 2/2 and AAV 2/9 both showed ability to successfully transduce the ocular 
surface. g) Fluorescent microscopy revealed AAV 2/9 successfully transduced all 
corneal layers following an intracameral injection – 7 days post injection the eyes were 
harvested for cryosectioning and fluorescent microscopy. AAV 2/9 demonstrated potent 






Figure 3: a) Schematic to show novel PAM generated with the L450W FECD mutation 
– TTG>TGG results in the creation of  a novel S.pyogenes PAM (5’ – NGG – 3’) on the 
mutant allele indicated by the red box, at this position on the wild-type allele there is a non-
canonical PAM NTG shown by the green box. A guide was designed utilising this novel PAM, 
shown by the orange box, Cas9 should only recognise NGG as a PAM therefore allele-specific 
cleavage should be achieved. b) Assessment of allele discrimination of sgLW via an in 
vitro digest - An in vitro digest was used to initially test the allele discrimination of the 
designed sgRNA, the mutant allele appears to be preferentially cleavage when compared to 















Figure 4: a) Schematic of the dual-AAV-2/9 CRISPR/Cas9 vectors utilised b) Output of 
TIDE analysis performed on a PCR product generated on whole cornea DNA extracted 
















6 Paper V - Gene editing in the context of an increasingly complex genome 
Blighe K*, DeDionisio L*, Christie KA*, Shareef S, Kakouli-Duarte T, Chao-Shern C, 
Harding V, Kelly RS, Stebbing J, Castellano L, Chawes B, Shaw JA, Lasky-Su JA, Nesbit MA, 
Moore CBT 
* These authors are co-first authors Aim 
6. 1 Aims and author contributions 
The main aims of this paper were to: 
1. Highlight the complexities of the genome in relation to regulation of expression and 
role in disease mechanism 
2. Encourage readers to progress from a ‘linear’ interpretation of the genome to that 
which encompasses a greater appreciation of the folding of the DNA molecule, DNA-
RNA and -protein interactions, etc., and how these regulate expression and contribute 
to disease mechanism. 
3. Focus on gene editing via CRISPR/Cas9 as a key technique that is likely to bring 
about the next frontier. 
Contribution 
I authored the ‘Complex genetics, complex disease:  room for gene editing?’ section and the 
































































































Gene therapy holds immense promise for the treatment of single gene diseases. The potential 
to correct disease at the level of the gene offers hope for these devastating diseases. However, 
past tragedies in the field of gene therapy, such as the untimely death of Jesse Gelsinger due to 
an overreaction to adenovirus and the death of 5 patients in a clinical trial for X-SCID due to 
insertional mutagenesis1,2, have highlighted that we must enter this new age with great caution. 
Tremendous progress has been made in the field of gene therapy, such as the vast expansion of 
the toolkit and a greater appreciation for associated risks for these applications. However, there 
are still several pinnacle questions, such as genome-wide specificity, efficiency and delivery, 
that must be addressed to bring about the next frontier in gene therapy.  
The work presented within this thesis establishes the groundwork for the development of a 
gene editing approach to treat the corneal dystrophies, a monogenic disease. However, the 
application of gene editing strategies to treat complex disease, in which a combination of alleles 
in addition to environmental factors can contribute to the risk of developing disease, is 
somewhat premature. Currently our understanding of complex disease, prevents the direct 
extension of this work to diseases dictated by complex genetics. Paper V discusses the immense 
progress made in both our understanding and interpretation of human disease since the 
completion of the human genome project. For mendelian monogenic diseases, such as the 
corneal dystrophies, focus at the level of the DNA has been sufficient to identify the disease-
causing variants. However, for complex disease a greater appreciation of the vast number of 
potential interactions will be absolutely critical in determining the genetic factors behind these 
common diseases and how their interactions result in disease. The fusion of a catalytically dead 
Cas9 to various protein effectors, such as a KRAB effector domain or chromatin-modifying 
enzymes, has enabled the generation of tools capable of interrogating the complexities of 




therapy landscape, it has become an indispensable technology to further our understanding of 
human disease. 
7.1 Role of TGFBIp in TGFBI corneal dystrophies 
The pathomechanism of TGFBI corneal dystrophies has not been fully elucidated. Several links 
have been made between the susceptibility of mutant TGFBIp and oxidative stress. Granular 
corneal dystrophy type II (GCD2) corneal fibroblasts were shown to be in oxidative stress and 
more susceptible to oxidative damage than their wild-type counterparts3. In addition, their 
membrane potential and mitochondrial activity was significantly reduced4. When mutant 
TGFBIp was exposed to superoxide species it was less stable and produced markedly more 
amyloid fibrils than wild-type TGFBIp5. These independent studies all indicate mutant 
TGFBIp has an increased susceptibility to oxidative stress. The cornea is continually exposed 
to ultraviolet light, with 90% of incident UV-B radiation known to be absorbed by the cornea6. 
Incidentally, UV-B radiation is known to be the main driver of superoxide species, resulting in 
oxidative stress7. It is conceivable that the susceptibility of mutant TGFBIp to the oxidative 
stress caused by the continual exposure of the cornea to UV light could have an important role 
in the pathomechanism of TGFBI corneal dystrophies.  
Furthermore, proteolytic degradation of mutant TGFBIp has been shown to be impaired.  The 
rate of protein clearance from GCD2 corneal fibroblasts was measured following treatment 
with a protein synthesis inhibitor8. Wild-type TGFBIp was cleared rapidly, whereas mutant 
TGFBIp remained after 1 hour. This effect was again observed when mutant TGFBIp was 
introduced into wild-type corneal fibroblasts. Together this indicates defective extracellular 
excretion or degradation of mutant TGFBIp in respect to wild-type TGFBIp. In addition, 
abnormal turnover of mutant TGFBIp from corneas associated with R124C, R124H and R124L 




missense mutations studied were shown to have abnormal turnover, however differential 
protein processing was observed for each mutation. As these 3 missense mutations all affect 
the same residue this may indicate how such strikingly different corneal dystrophy phenotypes 
are observed for each mutation. TGFBIp was found to be significantly increased in corneas 
with R124C, R124H and R124L, compared to wild-type corneas, in addition it was found that 
TGFBIp co-localised with the pathogenic deposits10. Again indicative that degradation of 
mutant TGFBIp is impaired. This was confirmed in an additional report that investigated the 
proteomic composition of R124C deposits, causative of lattice corneal dystrophy, to R555W 
deposits, causative of granular corneal dystrophy7. All deposits were shown to contain TGFBIp 
as previously reported, however the remaining constituents varied between LCD and GCD, 
indicating they undergo different proteolytic processing suggesting a possible reasoning for the 
phenotypic heterogeneity exhibited by these missense mutations.  
Missense mutations within TGFBI have not been shown cause adverse phenotypes in other 
tissues in body. The cornea exists as the only transparent connective tissue in the body, its 
fundamental function is to maintain transparency11. TGFBI corneal dystrophies result in a 
disease phenotype due to the accumulation of mutant proteins in the corneal stroma that impair 
its function to remain transparent. Taken together a potential mechanism of disease exists 
whereby; under oxidative stress the normal degradation pathways implemented to eliminate 
TGFBIp are not sufficient, leading to abnormal proteolytic processing of the mutant protein 
which results in an accumulation of mutant protein and thus the formation of these blinding 
deposits.   
It has been extensively reported that when patients who have an underlying TGFBI mutation, 
but a seemingly quiet cornea i.e. do not exhibit symptoms associated with corneal dystrophy, 




15. In Paper III, the loss of TGFBIp is shown to negatively affect the wound healing process in 
a regenerating zebrafish tail-fin. This result is important in explaining why patients see a 
sudden emergence of deposits following laser eye surgery. In addition, it contributes to the 
understanding of the pathomechanism of TGFBI corneal dystrophies. Tissue damage, such as 
a tail-fin amputation or laser eye surgery initiates wound healing pathways, such as the TGFβ 
signalling pathway, which results in an upregulation of TGFBI expression. Thus, there is an 
increased production of mutant TGFBIp in the cornea which is unable to be degraded. 
Therefore, triggers the accumulation of opacities which impair the function of the transparent 
cornea. Importantly, this result provides insight into the concentration of mutant TGFBIp 
required to result in deposit formation. Prior to laser eye surgery these patients did not show 
symptoms of corneal dystrophies, indicative that when mutant TGFBIp is present at very low 
levels deposits do not form. This provides insight into the levels of mutant allele disruption that 
may be required to restore a normal phenotype in corneal dystrophy patients. Perhaps the 
presence of mutant TGFBIp in the cornea below a certain threshold does not result in disease, 
however passing this threshold results in deposit accumulation. Furthermore, it has 
implications on prospective gene therapy strategies for the TGFBI corneal dystrophies, the 
obvious role of TGFBIp in wound repair suggests complete knockout of the TGFBI gene would 
be inadvisable, as it would result in a cornea unable to mount a sufficient response to potential 
damage.  
Zebrafish have become a popular model to study wound healing due to their capacity to 
regenerate tissues and the ease of genetic manipulation. As zebrafish tail-fins are relatively 
simple, symmetric structures they offer an ideal tissue to assess a gene’s role in wound healing. 
Within this thesis tgfbi knockdown in a zebrafish tail-fin was shown to impair tail-fin 
regeneration. While this is an interesting finding, the ambiguity of how TGFBIp results in the 




wound repair plays a role in this process are outstanding. To date no corneal epithelial wound 
healing studies in zebrafish have been published, however the ability of the zebrafish corneal 
endothelium to regenerate has been demonstrated16,17. Following confirmation of the 
regenerative capacity of the zebrafish corneal epithelium this finding could be validated by 
comparing the corneal regeneration rates following corneal injury in a wild-type zebrafish and 
a tgfbi deficient zebrafish.  
Recently Poulsen et al performed a proteomic comparison of wild-type mice and mice deficient 
in Tgfbi (Tgfbi-/-)18. However, they found minimal difference in the protein composition of the 
two corneas. The results from the regenerating tail-fin assay indicate that the predominant role 
of TGFBIp is in wound repair. Thus, future work may encompass inducing corneal injury in 
both wild-type and Tgfbi-/- mice and assessing the proteomic composition of the injured 
corneas. Superficial corneal injury could be induced by using a trephine to mark a wound size 
and employing rotating burr to remove the epithelium and basement membrane within the 
mark. The rate of wound closure can then be monitored by staining the wound with fluorescein 
and imaging the mice in vivo at different timepoints. Corneas can then be dissected at an 
appropriate timepoint and subjected to mass-spectrometry analysis to compare the proteomic 
profile of uninjured and injured corneas. This would provide insight into the pathways involved 
in corneal wound repair and how complete removal of TGFBIp impacts upon this.  
7.2 Mutation-dependent allele-specific editing of the TGFBI corneal dystrophies  
The demonstration of the critical role of TGFBIp in wound repair in Paper III highlights the 
need to maintain a functional copy of TGFBI in the cornea. Repair the TGFBI missense would 
be a potential treatment strategy, Taketani et al demonstrated this is patient-derived primary 
corneal keratocytes. However, the efficiency of homology directed repair is currently too low 




recombination is only applicable ex vivo19. Patient cells are CRISPR treated ex vivo and clones 
harbouring the desired edit are expanded and these clonal cells can be reintroduced into the 
body. This is approach is particularly effective in diseases of the blood, such as sickle cell 
anaemia20. For corneal gene editing, a limbal biopsy would be taken, which could contain 
limbal epithelial stem cells (LESCs). The LESCs would be edited ex vivo and reintroduced 
into the patient’s cornea. However, in order for the clonal edited cells to repopulate the cornea, 
resident stem cells in the corneal would have to be completely removed. This would induce 
limbal stem cell deficiency (LSCD) which is an extremely severe condition. The risk that the 
graft of clonally edited LESCs would not take is too high, thus this would not be a feasible 
treatment strategy for the corneal dystrophies. However, an approach that selectively disrupts 
the mutant allele and leaves the wild-type allele intact would be a viable treatment option. 
Disruption of the PAM sequence is known to impair Cas9 function21–23, therefore utilising the 
generation of a SNP-derived PAM to achieve allele-specific editing of a missense mutation 
offers a promising treatment strategy. Previous reports indicated that in cases where the 
missense mutation generates a novel PAM stringent allele-specificity can be achieved24–26. 
However, mutational analysis of the 62 missense mutations associated with the TGFBI corneal 
dystrophies revealed <1/3 generate a novel PAM. Critically, the 5 most prevalent mutations 
(R124H, R124C, R124L, R555Q and R555W) do not generate a novel S.pyogenes PAM but 
have a PAM nearby. Thus an alternative approach to PAM-specific allele-specific editing, 
termed guide-specific allele-specific editing, in which the missense mutation is incorporated 
into the guide sequence, was explored for these prevalent mutations. Paper II reports the 
inadequacies of this guide-specific approach in comparison to the PAM-specific approach. The 
guide-specific approach appeared to confer differing specificities depending on the position of 
the missense mutation within the guide sequence, with PAM-proximal mutations offering 




S.pyogenes Cas9 to single base pair mismatches within the guide sequence27–29. In addition, 
these reports have implicated the region immediately adjacent to the PAM as critical in 
determining specificity validating the results observed in Paper II.  
Smith et al explored a guide-specific approach to treat α1-antitrypsin (AAT) deficiency. They 
designed a guide incorporating the missense mutation at postion 5 within the guide sequence. 
They demonstrated clear discriminate between wild-type and mutant alleles in patient-derived 
iPSCs, albeit at very low efficiencies of ~1%30. Yamamoto et al sought to develop a guide-
specific approach to treat QT syndrome. They designed a guide incorporating the missense 
mutation at position 1 in guide, however they opted for a nickase approach to improve genome 
wide specificity31. Again they observed very low efficiencies but successfully isolated two 
clones with a frameshifting mutation on only the mutant allele. Burnight et al developed an 
approach to selectively disrupt the mutant allele in the P23H mutation associated with retinitis 
pigmentosa32. They utilised S.aureus Cas9 and designed a guide incorporating the missense 
mutation at position 3 in the guide sequence. Within patient-derived iPSCs they achieved very 
high indel frequencies and report the majority of indels occur only with the mutant allele. 
Interesting, Li et al published a comprehensive report of allele-specific editing also targeting 
the P23H retinitis pigmentosa mutation in vivo33. They used engineered S.pyogenes variants 
SpCas9-KKH and SpCas9-VQR, recognising NNCAGT and NGA PAMs respectively 22,34. 
Guide design incorporated the P23H mutation at position 4 or 12 within the guide sequence. 
However, neither nuclease variant was able to discriminate between the single base pair in vivo. 
Truncation of the guide sequence has been shown to improve specificity35, truncation of the 
guide from 20bp to 17bp enabled the nuclease variants to distinguish between the two alleles. 
Finally, Gao et al investigated a guide-specific approach to treat autosomal dominant hearing 
loss caused by the M412K mutation in TMC136. They investigated four different S.pyogenes 




sequence, the fourth guide was a truncated from of the guide containing the mutation at position 
6. Using RNPs they achieved good allele discrimination in mouse primary fibroblasts 
(TmcM412K/+). In vivo they only observed 0.92% indel frequency which they report to 
predominantly occur with the mutant allele. Surprisingly, they found that 0.92%, which 
equated to around 1.8% disruption of the mutant allele, was enough to ameliorate hearing loss. 
These reports describe differing efficiencies based on the model and the Cas nuclease utilised. 
Indicating that application of a guide-specific approach requires individual assessment of the 
target sequence and cell type in which allele-specific editing is necessary. 
Paper II relied solely on an in vitro readout of allele-specificity, using a dual-luciferase assay 
and an in vitro digest, and perhaps provided an overestimate of wild-type allele cleavage. In 
order to adequately demonstrate allele-specific cleavage ex vivo or in vivo a patient-derived 
cell line or mouse model for each mutation studied would have been required, which were not 
readily available. In lieu of these models two in vitro assays were used in parallel to assess 
allele-specificity. While both assays are widely accepted techniques they both have limitations 
affecting their reliability. In the case of the dual-luciferase assay three separate plasmids are 
co-transfected into AD293 cells; a plasmid expressing firefly luciferase with a target sequence 
of the gene of interest cloned into the 3’UTR of firefly luciferase, a plasmid expressing Cas9 
and a sgRNA targeted to the gene of interest, and a plasmid expressing renilla luciferase. The 
ability for Cas9 to cleave the target site causes the plasmid to be linearised, RNA polymerase 
will not be able to reach the poly A tail, thus the mRNA will be degraded, resulting in a 
reduction in firefly luciferase activity. Firefly luciferase is normalised to renilla luciferase as 
an attempt to control for transfection efficiency. However, this assay relies on the assumption 
that all cells are transfected with the same copy number of each plasmid and that all plasmids 
are expressed at an equivalent level. The considerable variation in copy number and expression 




DNA template containing the target site with a ribonucleoprotein (RNP) complex of Cas9 and 
a sgRNA targeted to the target site. The ratio of Cas9:sgRNA:target can be controlled for, 
making comparison of cleavage at different target sites more reliable. However, this assay is 
not carried out in a cellular context so may have little resemblance to how Cas9 will behave in 
vivo.  Despite these limitations both assays indicated that a mutation dependent approach that 
relied upon a single base pair mismatch within the guide sequence could not confer stringent 
specificity. This finding is not surprising when considered in the context of genome-wide 
specificity, Cas9 is known to cleave at sites elsewhere in the genome that differ to the target 
site by several mismatches. The likelihood that Cas9 will be faced with a genomic off-target 
site equipped with an adjacent PAM and only a single base pair mismatch is extremely low. 
Thus, allele-specific editing presents a novel class of off-targets that are more challenging to 
address than genome-wide off-target sites. The ability to discriminate between alleles using the 
20bp guide sequence instead of the 2bp PAM sequence would offer ~10 fold improved 
flexibility in identifying a suitable target site. Currently available CRISPR nucleases do not 
possess the degree of specificity required to tackle this class of off-target site. To overcome 
this future work will involve using directed evolution to engineer a Cas9 nuclease that has the 
capabilities to achieve single nucleotide resolution. A library of variant Cas9 nucleases will be 
generated and tested in a bacterial selection and counter selection system that will isolate Cas9 
variants that cleave the on-target site but do not cleave an off-target site differing by a single 
base pair mismatch. These variants will then be tested in mammalian cells for their ability to 
achieve allele-specific editing with clinically relevant SNPs. 
7.3 Mutation-independent allele-specific editing of the TGFBI corneal dystrophies 
Paper II indicated the limitations associated with a mutation-dependent approach. While 
stringent allele-specificity can be achieved with a PAM-specific approach or a context 




cases where several mutations are associated with the disease. Paper II revealed that when 
employing S.pyogenes Cas9 20% of the known TGFBI missense mutations were not targetable 
by either approach, 30% generated a novel PAM while the remaining mutations were only 
targetable by a guide-specific approach. Thus, in Paper III an approach that removes the 
constraints of mutation-dependent targeting was investigated. As the specificity rules for PAM-
generating SNPs are well established this mutation-independent approach maintains this 
mechanism to achieve specificity. It utilises commonly occurring SNPs that are associated with 
a PAM on the same allele as the disease causing mutation. Shin et al reported the use of the 
extensive knowledge of the huntington (HTT) gene haplotypes37, encompassing the 
trinucleotide repeat (TNR) associated with Huntington’s disease, to achieve allele-specific 
disruption of HTT 38. For HTT, screening of only 10 SNPs is sufficient to provide haplotype 
information for 97% of the European Huntington’s disease patients37. However, in the case of 
TGFBI missense mutations phase cannot be pre-determined, there is no subtle way to predict 
the phasing of these missense mutations.  
Building on previous work we developed an approach for the TGFBI corneal dystrophies that 
would enable allele-specific targeting of the TGFBI locus of a patient harbouring any missense 
mutation, provided some heterozygosity exists in their haplotypes across the TGFBI locus. This 
approach was coined allele-specific, SNP-derived, in cis, personalised, CRISPR (ASNIP 
CRISPR). A major limitation of this approach is that it requires the design of common intronic 
guides that could be used in combination with the ASNIP guides. This would enable a dual-
guide approach with minimal intervening distance that is capable of efficiently excising a 
portion of TGFBI coding sequence. The application of this modification would require 
complete assurance that the intronic region targeted does not contain any regulatory elements. 
As the diverse functions and actions of non-coding RNAs are still largely unknown this may 




(NNGRRT)40 or AsCas12a (TTTN)41 or indeed nucleases with engineered PAM 
specificities34,42, could also be assessed for the identified common SNPs across the TGFBI 
locus. This would enable two allele-specific ASNIP guides in close proximity to be utilised to 
achieve an excision of the TGFBI coding region. The Cas nuclease toolkit is continually 
expanding, with a diverse repertoire of targetable PAMs the ASNIP approach holds vast 
potential.  
Haplotype analysis of 24 SNPs within the TGFBI coding region that matched the ASNIP 
criteria was performed to determine the proportion of the East Asian population that could be 
targeted by this approach. Interestingly, the R124H patient with which phased sequencing was 
performed differed at one position to the predicted haplotype, indicating that recombination 
had occurred at this positon. This highlights that the haplotype predictions cannot be solely 
relied upon for determining at which site targetable SNPs occur. Furthermore, in this new era 
of personalised medicine where progress will be made with great caution whole genome 
sequencing (WGS) will undoubtedly be a requisite for any patient undergoing any form of gene 
editing therapy, in order to fully comprehend the success or failure of such therapies. As an 
extension to this whole-genome phased sequencing will allow the design of guides in cis with 
the mutation for autosomal disease but will also aid in the understanding of outcomes should 
unwanted off-targets effects or chromosomal translocations occur. Therefore, obligatory 
whole-genome phased sequencing would be essential to help ensure safe and successful 
treatment using ASNIP CRISPR.   
7.4 Delivery of CRISPR/Cas9 components to the corneal layers 
Due to the role of the cornea as a structural barrier to prevent entry of foreign substances into 
the eye, delivery to the corneal layers has proven to be quite a challenge. To-date, topical 




was investigated for its ability to transduce the corneal layers in vivo following an intracameral 
injection. Excitingly, AAV-2/9 demonstrated the ability to transduce all corneal layers 
following an intracameral injection. In addition, packaging of CRISPR/Cas9 components into 
a dual-AAV system achieved 25.7% indel frequency in the whole cornea.  This provides a 
potential vector that could be used to deliver gene editing reagents targeted to corneal 
dystrophies associated in any corneal layer. Identifying or developing a delivery vehicle 
capable of delivery to the corneal layers following topical application would revolutionise 
ocular gene therapy, encouraging uptake by both clinicians and patients. Further work may 
entail directed evolution of a AAV vector that can transduce corneal cells following topical 
application. A library of mutant AAV vectors would be produced, which would be topically 
applied to a cornea ex vivo. AAV vectors can then be isolated from a specific layer or from the 
posterior side of the cornea, indicating that they have successfully transduced the desired region 
of the cornea following topical application.  
Basche et al published a report just this month demonstrating that a systemic injection of AAV-
2/9 results in transduction of the corneal epithelium, stroma and endothelium44. Furthermore 
AAV-2/9 appeared to transduce the LESCs, evidenced by sustained centripetal streaks from 
the limbus. This report validates our observation and importantly indicates that AAV-2/9 has 
the ability to transduce the LESCs. However, this report also highlights that delivery vehicles 
are capable of transporting from other areas of the body to the eye. This raises considerable 
concerns about utilising viral vectors for gene therapy. AAV has become perhaps the most 
widely used delivery vector, due to its low immunogenicity. However, commonly utilised AAV 
vectors result in sustained expression of the viral transgene. Thus, when utilised to deliver 
CRISPR/Cas9 components there will be continual production of Cas9:sgRNA, increasing the 
likelihood of off-target cleavage. Gao et al report that assessment of off-target cleavage in 




with efficiencies ranging from 0.68-8.1%, while off-target cleavage using RNPs produced indel 
at only 1/10 sites at an efficiency of 1.2%36. This ability of RNPs to achieve higher genome-
wide specificity than plasmid is well accepted45,46. This is due to continual expression of 
CRISPR/Cas9 components by the plasmid compared to limited exposure time of the RNPs. 
Therefore an in vivo delivery system such as, as nanoparticles or cationic lipids, with the ability 
to deliver RNPs to the target cell type would be provide a much safer delivery vehicle 47,48. 
This is an important consideration for gene editing in all contexts, but most critically for allele-
specific editing. The wild-type allele exists as an almost perfect off-target site, with only a 
single base pair mismatch. It is extremely unlikely that Cas9 will be faced with such an off-
target elsewhere in the genome. However, for allele-specific editing this off-target will always 
occur and it presents the most hazardous off-target site as cleavage here will unintentionally 
ablate the functional protein. Cas9 requires exquisite specificity to distinguish between the two 
alleles. As viral delivery will promote continual expression of the CRISPR components 
eventual cleavage at the wild-type allele will almost certainly occur. Delivery to the corneal 
layers and desired cell type, such as the LESCs, keratocytes or corneal endothelial cells, 
utilising a non-viral delivery vehicle will again aid in genome-wide specificity. Future work 
will entail assessing the delivery of CRISPR/Cas9 RNP complexes to the cornea using iTOP, 
a non-viral delivery agent shown to have achieved gene editing of both muscle and retinal cells 
in vivo49. iTOP (induced transduction by osmocytosis and propanebetaine) uses a combination 
of NaCl hypertonicity-induced micropinocytosis and a transduction compound 
(propanebetaine) to induce highly efficient transduction of proteins into cells. An Ai9 mouse 
model in which a loxP-flanked STOP cassette prevents transcription of a red fluorescent 
protein variant (tdTomato), will be used to assess delivery via these non-viral agents50. Initially, 
Cre recombinase will be used to monitor successful delivery to the cornea using non-viral 




loxP sites the STOP cassette will be removed and tdTomato will be expressed. Cre in complex 
with these agents will be assessed in various routes of administration, including topical 
application, intrastromal injection and intracameral injection. Observation of tdTomato using 
the IVIS in vivo imager and confirmation of transduction via fluorescent microscopy will 
indicate successful delivery of Cre recombinase to the cornea using non-viral reagents. At the 
outset milder formulations will be used, if no tdTomato signal is observed a more concentrated 
buffer will be tested. Following successful delivery of Cre recombinase to the corneal layers, 
CRISPR RNPs will be complexed with the iTOP buffer. The ability of iTOP to deliver CRISPR 
RNPs targeted to the loxP sites to the cornea will then be assessed using the IVIS in vivo 
imager. Confirmation of gene disruption will be confirmed using targeted resequencing. 
Successful transduction of the corneal layers using a non-viral delivery agent would provide a 
promising alternative to viral delivery, in which the expression of the CRISPR components 
would be limited thus reducing the propensity of Cas9 to cleave the wild-type allele. 
7.5 Conclusion 
While this thesis presents considerable progression towards a personalised genome editing 
strategy to treat the corneal dystrophies, substantial work still remains to be done. The work 
presented within highlights the current limitations of CRISPR/Cas9 gene editing, such as a lack 
of global specificity and inadequate delivery vehicles. The remaining issues are not isolated to 
corneal gene therapy but extend to all gene therapy applications. Adequately addressing these 
outstanding hurdles will enable the safe translation of these therapies to the clinic. The genome-
wide specificity of CRISPR/Cas9 persists as a major concern for the clinical use of this 
nuclease. The Cas nucleases are evolved for use in a bacterial genome which are considerably 
smaller in size, thus wild-type nucleases do not possess the on-target fidelity required to edit 
the mammalian genome. Critically, this has massive implications for allele-specific editing, as 




nucleases capable of nuclease specificity will be paramount to the safe and successful 
translation of allele-specific genome editing applications to the clinic. Furthermore, viral 
vectors have been successful gene replacement vectors in gene therapy applications thus far, 
in which persisted expression is advantageous to continually produce the functional protein. 
However, persisted expression in the case of genome editing and particularly allele-specific 
genome editing will increase the likelihood of off-target cleavage. Thus, exploration of a non-
viral alternative to delivery gene-editing reagents to the cornea is essential to ensure cleavage 
only occurs at the target site. CRISPR/Cas9 has revolutionised the field of molecular biology, 
providing an unrivalled tool to investigate gene function and human disease. Beyond this it 
holds huge promise for the treatment of devastating single gene diseases. While this is an 
immensely exciting time in the field of gene therapy, the progression to the clinic must not be 
made with haste. Appropriately addressing the current limitations of a lack of specificity and 
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